Delayed sustained release oral drug dosage forms of Janus kinase (JAK) inhibitors and methods of use thereof

JP2023551997A5Inactive Publication Date: 2024-12-06TRIASTEK INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534652
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-08
Filing Date
2021-12-08
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for diseases associated with the Janus kinase (JAK)-STAT signaling pathway, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, primarily focus on symptom alleviation and do not address the severity of morning symptoms experienced by patients, necessitating improved drug delivery systems to enhance therapeutic efficacy.

Method used

Development of delayed sustained release oral drug dosage forms of JAK inhibitors, incorporating a delayed release component and a shell that prevents the release of the JAK inhibitor for a specified period, allowing for controlled drug delivery to alleviate symptoms during sleep and upon waking.

Benefits of technology

The delayed release mechanism ensures consistent drug levels overnight, providing relief upon waking and improving treatment compliance and quality of life by reducing morning stiffness and other symptoms associated with these diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided are delayed-release oral drug dosage forms comprising a Janus kinase (JAK) inhibitor, such as tofacitinib. In other aspects, provided are methods of designing, making, such as using three-dimensional printing, and methods of treatment and / or prophylaxis associated with the oral drug dosage forms described herein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority over International Application PCT / CN2020 / 134653, filed on 8 December 2020, which is incorporated herein by reference in its entirety.

[0002] In some embodiments, this disclosure covers delayed-release oral drug formulations, including Janus kinase (JAK) inhibitors such as tofacitinib. In other embodiments, this disclosure provides methods for designing, manufacturing, including using three-dimensional printing, and therapeutic and / or preventive methods associated with the oral drug formulations described herein. [Background technology]

[0003] The Janus kinase signaling and activator of transcription protein (JAK-STAT) signaling pathway, comprising numerous members including the Janus kinase enzyme family, is involved in many fundamental biological processes such as apoptosis, inflammation, and autoimmunity. The JAK-STAT signaling pathway and its associated members are described, see, for example, Rawlings et al., J Cell Sci, 117, 2004, and Schwartz et al., Nat Rev Drug Discov, 17, 2017. Dysfunction of the JAK-STAT signaling pathway is involved in many human diseases, including cancer and immune system-related disorders such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and psoriasis. Many of these diseases are not curable, and treatment consists of approaches that simply attempt to mitigate the effects of the associated symptoms. For example, patients with rheumatoid arthritis and psoriatic arthritis often suffer from morning stiffness caused by periods of inactivity during sleep. Similarly, patients with ulcerative colitis often suffer from more severe symptoms earlier in the morning. All references cited herein, including patent applications and publications, are incorporated herein by reference in their entirety. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Rawlings et al., J Cell Sci, 117, 2004 [Non-Patent Document 2] Schwartz et al.,Nat Rev Drug Discov,17,2017 [Overview of the project] [Means for solving the problem]

[0005] In some embodiments, the foregoing provides a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor, the delayed-release oral drug dosage form comprising a sustained-release drug component comprising a first corrosive material mixed with a JAK inhibitor, and a delaying component, the delaying component preventing the release of the JAK inhibitor from the delayed-release oral drug dosage form for about 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human subject.

[0006] In some embodiments, the delay component comprises a delay member containing a second corrosive material not mixed with the JAK inhibitor, and a shell, and the delay component completely surrounds the sustained-release drug component. In some embodiments, the sustained-release drug component is a layer having a top surface and a bottom surface. In some embodiments, the top surface of the sustained-release drug component is not flat. In some embodiments, the thickness measured between the top surface and the bottom surface is substantially consistent.

[0007] In some embodiments, the sustained-release drug component is embedded in the shell such that the bottom and sides of the sustained-release drug component are in direct contact with the shell.

[0008] In some embodiments, the upper surface of the sustained-release drug component is not in direct contact with the shell.

[0009] In some embodiments, the delay member is a layer having a top surface and a bottom surface. In some embodiments, the top surface of the delay member is not flat. In some embodiments, the thickness measured between the top surface and the bottom surface is substantially consistent.

[0010] In some embodiments, the bottom surface of the delaying member, or a portion thereof, is in direct contact with the uppermost layer of the sustained-release drug component.

[0011] In some embodiments, the sides of the delay member are in direct contact with the shell.

[0012] In some embodiments, a portion of the bottom surface of the delay member is in direct contact with the shell. In some embodiments, the portion of the bottom surface of the delay member that is in direct contact with the shell forms a perimeter that extends beyond the upper surface of the sustained-release drug component.

[0013] In some embodiments, the delay member and the shell are configured to prevent the JAK inhibitor from being released from the delayed-release oral drug formulation until the delay member is corroded.

[0014] In some embodiments, the shell comprises an isolation material that is impermeable to body fluids. In some embodiments, the isolation material is a non-corrosive material. In some embodiments, the isolation material is a corrosive material having a pH-sensitive corrosion and / or corrosion rate that allows for the complete release of the JAK inhibitor from the delayed-release oral drug dosage form before exposure of the sustained-release drug component to body fluids due to corrosion of the shell.

[0015] In some embodiments, the delayed-release oral drug dosage form has a substantially flat top surface. In some embodiments, the top surface is formed by a delay member and a shell. In some embodiments, the shell includes an insertion portion having depth, and the delay member is configured to fit into the insertion portion of the shell. In some embodiments, the thickness of the delay member is the same as the depth of the insertion portion of the shell. In some embodiments, the top surface is capsule-shaped.

[0016] In some embodiments, the upper surface of the sustained-release drug component is capsule-shaped.

[0017] In some embodiments, the upper surface of the delay member is capsule-shaped.

[0018] In some embodiments, the delaying component prevents the release of the JAK inhibitor from the delayed-release oral drug formulation for approximately 2 to 4 hours after administration to a human subject.

[0019] In some embodiments, the delaying component prevents the release of the JAK inhibitor from the delayed-release oral drug formulation for approximately 2 to 3 hours after administration to a human subject.

[0020] In some embodiments, the sustained-release drug component is configured to release the JAK inhibitor from the delayed-release oral drug formulation in the following manner: (i) less than 30% of the total JAK inhibitor is released 1 hour after complete corrosion of the delaying component or a portion thereof; (ii) more than 35% and less than 75% of the total JAK inhibitor is released 2.5 hours after complete corrosion of the delaying component or a portion thereof; and (iii) more than 75% of the total JAK inhibitor is released 5 hours after complete corrosion of the delaying component or a portion thereof.

[0021] In some embodiments, the release of the JAK inhibitor is based on the in vitro release rate.

[0022] In some embodiments, when administered to a human subject, the mean area under the plasma concentration-time curve after complete corrosion of the delayed component or a portion thereof ranges from approximately 17 ng-hr / mL per 1 mg of administered JAK inhibitor to approximately 42 ng-hr / mL per 1 mg of administered JAK inhibitor.

[0023] In some embodiments, T max This occurs approximately 6 hours after the complete corrosion of the retarding component or a portion thereof.

[0024] In some embodiments, when administered to a human individual, geometric mean plasma C max vs C min The ratio is approximately 10 to 100.

[0025] In some embodiments, the release of the JAK inhibitor is based on an in vitro elution technique that includes the use of a USP rotary paddle apparatus rotated at approximately 50 rpm and a test medium containing 900 mL of 0.05 M potassium phosphate buffer at pH 6.8 and 37°C.

[0026] In some embodiments, the upper surface of the sustained-release drug component is approximately 20 mm 2 ~400mm 2 It has a surface area of ​​[value].

[0027] In some embodiments, the upper surface of the sustained-release drug component has a maximum transverse dimension of approximately 5 mm to approximately 20 mm.

[0028] In some embodiments, the upper surface of the sustained-release drug component has a transverse dimension perpendicular to a maximum transverse dimension of about 2 mm to about 20 mm.

[0029] In some embodiments, the sustained-release drug component has a thickness of about 0.2 mm to about 5 mm.

[0030] In some embodiments, the sustained-release drug component is a drug mass fraction (m) of the JAK inhibitor, with a concentration of approximately 0.2 to approximately 0.6. F ) has.

[0031] In some embodiments, the sustained-release drug layer has an in vitro elution rate of approximately 2% to approximately 40% per hour, based on an in vitro elution technique that includes the use of a USP rotary paddle device rotated at approximately 50 rpm and a test medium containing 900 mL of 0.05 M potassium phosphate buffer at pH 6.8 and 37°C.

[0032] In some embodiments, the first corrosive material of the sustained-release drug component comprises one or more of hydroxypropyl cellulose (HPC EF), vinylpyrrolidone-vinyl acetate copolymer (VA64), triethyl citrate (TEC), and glycerin.

[0033] In some embodiments, the first corrosive material of the sustained-release drug component comprises about 35 w / w% to about 45 w / w% HPC EF, about 5 w / w% to about 15 w / w% VA64, and about 10 w / w% to about 20 w / w% glycerin.

[0034] In some embodiments, the upper surface of the delay member is approximately 20 mm 2 ~400mm 2 It has a surface area of ​​[value].

[0035] In some embodiments, the upper surface of the delay member has a maximum transverse dimension of about 5 mm to about 20 mm.

[0036] In some embodiments, the upper surface of the delay member has a transverse dimension perpendicular to a maximum transverse dimension of about 2 mm to about 20 mm.

[0037] In some embodiments, the delay member has a thickness of about 0.2 mm to about 5 mm.

[0038] In some embodiments, the delayed release of the oral drug formulation is fully dissolved approximately 6 hours after administration to a human subject.

[0039] In some embodiments, the second corrosive material of the retarding layer comprises one or more of hydroxypropyl cellulose (HPC EF), triethyl citrate (TEC), and titanium dioxide.

[0040] In some embodiments, the delay layer contains approximately 80 w / w% to 90 w / w% HPC EF, approximately 10 w / w% to 20 w / w% TEC, and approximately 0.1 w / w% to 0.3 w / w% titanium dioxide.

[0041] In some embodiments, the shell has a maximum transverse dimension of approximately 5 mm to approximately 20 mm.

[0042] In some embodiments, the shell has a transverse dimension perpendicular to a maximum transverse dimension of approximately 5 mm to approximately 20 mm.

[0043] In some embodiments, the delayed-release oral drug dosage form has a thickness of about 0.2 mm to about 15 mm.

[0044] In some embodiments, the shell has a minimum thickness of at least about 0.4 mm.

[0045] In some embodiments, the shell comprises one or more of ammonia methacrylate copolymer type B, ethylcellulose, stearic acid, and titanium dioxide.

[0046] In some embodiments, the shell contains about 60 w / w% to about 70 w / w% of ammonia methacrylate copolymer type B, about 10 w / w% to about 20 w / w% of ethylcellulose, about 15 w / w% to about 25 w / w% of stearic acid, and about 0.1 w / w% to about 0.3 w / w% of titanium dioxide.

[0047] In some embodiments, the JAK inhibitor interferes with the JAK-STAT signaling pathway. In some embodiments, the JAK inhibitor is one or more inhibitors of JAK1, JAK2, JAK3, or TYK2.

[0048] In some embodiments, the JAK inhibitor is tofacitinib or a pharmaceutically acceptable salt thereof. In some embodiments, the JAK inhibitor is tofacitinib citrate.

[0049] In some embodiments, the amount of JAK inhibitor in the delayed-release oral drug formulation is approximately 11 mg.

[0050] In some embodiments, the amount of JAK inhibitor in the delayed-release oral drug formulation is approximately 22 mg.

[0051] In some embodiments, the delayed-release oral drug dosage form is not the osmotically controlled-release oral drug dosage form.

[0052] In other embodiments, provided herein are commercial batches of any of the delayed-release oral drug formulations described herein, wherein the commercial batch has a standard deviation of about 0.05 or less for each of the following: the amount of JAK inhibitor in the delayed-release oral drug formulation, the weight of the delayed-release oral drug formulation, the maximum cross-sectional dimension of the delayed-release oral drug formulation, and the cross-sectional dimension perpendicular to the maximum cross-sectional dimension of the delayed-release oral drug formulation.

[0053] In some embodiments, a commercial batch comprises at least about 1000 delayed-release oral drug formulations.

[0054] In other embodiments, provided herein is a method for three-dimensional (3D) printing of any delayed-release oral drug dosage form described herein, comprising: (a) dispensing a delay component or a portion thereof; and (b) dispensing a sustained-release drug component comprising a first corrosive material mixed with a JAK inhibitor.

[0055] In some embodiments, discharging the delaying component includes (i) discharging a shell and (ii) discharging a delaying member comprising a second corrosive material not mixed with a JAK inhibitor.

[0056] In some embodiments, the discharge is via molten extrusion deposition (MED).

[0057] In some embodiments, the ejection of the delay component, the ejection of the shell, and the ejection of the delay member are performed by different print heads.

[0058] In other embodiments, the Specified herein provides a method for preparing a delayed-release oral drug dosage form of tofacitinib by three-dimensional (3D) printing, wherein the delayed-release oral drug dosage form comprises a shell containing an insoluble material, a pharmaceutical core containing tofacitinib, and a delay member not containing tofacitinib, and the method comprises (a) extruding an insoluble material to form a shell, (b) extruding a core material containing tofacitinib, and (c) extruding a delay member not containing tofacitinib.

[0059] In some embodiments, the discharge is via molten extrusion deposition (MED).

[0060] In some embodiments, each material is ejected by a different print head.

[0061] In other embodiments, the Specified herein provides a method for injection molding any oral drug dosage form described herein, comprising: (a) injecting a hot melt of a shell material into a mold cavity to form a shell; (b) injecting a hot melt of a first corrosive material mixed with a JAK inhibitor into the shell to form a sustained-release drug component; and (c) injecting a hot melt of a second corrosive material not mixed with a JAK inhibitor into the shell to form a delay member.

[0062] In other embodiments, provided herein is a method for injection molding any delayed-release oral drug dosage form described herein, comprising: (a) hot-melting a shell material, a first corrosive material mixed with a JAK inhibitor, and a second corrosive material not mixed with a JAK inhibitor; (b) delivering each material to its respective injection unit; (c) injecting the hot-melt shell material into a mold cavity to form a shell; (d) allowing the shell to cool and opening the mold to release the shell; and (e) transferring the shell to a male mold and injecting the first corrosive material mixed with a JAK inhibitor. The method comprises (f) injecting a hot melt of a first corrosive material mixed with a JAK inhibitor to form a sustained-release drug component, (g) allowing the sustained-release drug component to cool and opening the mold to release the shell and sustained-release drug component, (h) transferring the shell and sustained-release drug component to a male mold and injecting a second corrosive material not mixed with a JAK inhibitor to form a delay member, (i) injecting a hole molten form of the second corrosive material not mixed with a JAK inhibitor, and (j) discharging a delayed-release oral drug dosage form.

[0063] In some embodiments, the injection unit is selected from the group consisting of a single-screw injection unit, a plunger injection unit, and a gear pump injection unit. In some embodiments, steps (c) to (j) are performed sequentially. In some embodiments, steps (c), (f), and (i) are performed simultaneously. In some embodiments, steps (e), (h), and (j) are performed simultaneously.

[0064] In another embodiment, the foregoing provides a method for preventing morning stiffness caused by rheumatoid arthritis, the method comprising administering to a human individual a delayed-release oral drug formulation described herein, the delayed-release oral drug formulation being administered within approximately one hour of bedtime.

[0065] In another embodiment, the foregoing provides a method for preventing morning stiffness caused by psoriatic arthritis, the method comprising administering to a human individual a delayed-release oral drug formulation described herein, the delayed-release oral drug formulation being administered within approximately one hour of bedtime.

[0066] In other embodiments, the foregoing provides a method for treating ulcerative colitis, comprising administering to a human individual a delayed-release oral drug dosage form described herein.

[0067] It will be understood by those skilled in the art that modifications to the forms and details of the implementations described herein can be made without departing from the scope of this disclosure. In addition, although various advantages, embodiments, and purposes have been described with reference to various implementations, the scope of this disclosure should not be limited by reference to such advantages, embodiments, and purposes. [Brief explanation of the drawing]

[0068] [Figure 1A-B] An exemplary cross-sectional view of a delayed-release oral drug dosage form is shown. [Figure 1C-H] An exemplary cross-sectional view of a delayed-release oral drug dosage form is shown. [Figure 2A] A diagram illustrating an exemplary delayed-release oral drug dosage form is shown. [Figure 2B] A diagram illustrating an exemplary delayed-release oral drug dosage form is shown. [Figure 2C] A diagram illustrating an exemplary delayed-release oral drug dosage form is shown. [Figure 2D] A diagram illustrating an exemplary delayed-release oral drug dosage form is shown. [Figure 3] Dissolution plots for delayed-release oral drug formulations and commercially available sustained-release formulations are shown. [Figure 4] Dissolution plots for delayed-release oral drug formulations and commercially available sustained-release formulations are shown. [Figure 5] The mean plasma concentration-time curves after administration of delayed-release oral drug formulations and commercially available sustained-release formulations are shown. [Figure 6] The mean plasma concentration-time curves after administration of delayed-release oral drug formulations and commercially available sustained-release formulations are shown. [Figure 7] Dissolution plots for the three oral drug dosage forms described herein and commercially available sustained-release dosage forms are shown. [Figure 8] The mean plasma concentration-time curves after administration of delayed-release oral drug formulations and commercially available sustained-release formulations are shown. [Figure 9] The mean plasma concentration-time curves and target delayed-release plasma concentration-time curves after administration of delayed-release oral drug formulations and commercially available sustained-release formulations are shown. [Figure 10] This shows the dissolution plot for delayed-release oral drug formulations. [Figure 11A] The schematic diagrams for dosage forms D to I are shown below. [Figure 11B] The schematic diagrams for dosage forms D to I are shown below. [Figure 11C] The schematic diagrams for dosage forms D to I are shown below. [Figure 11D] The schematic diagrams for dosage forms D to I are shown below. [Figure 11E] The schematic diagrams for dosage forms D to I are shown below. [Figure 11F] The schematic diagrams for dosage forms D to I are shown below. [Figure 12] This shows the dissolution plot for delayed-release oral drug formulations. [Figure 13] The mean plasma concentration-time curves after administration of delayed-release oral drug formulations and commercially available sustained-release formulations are shown. [Figure 14] The dissolution plots for two delayed-release oral drug formulations are shown. [Figure 15] The mean plasma concentration-time curves after administration of two delayed-release oral drug formulations and a commercially available sustained-release formulation are shown. [Figure 16] The dissolution plots for two delayed-release oral drug formulations are shown. [Figure 17] The mean plasma concentration-time curves after administration of two delayed-release oral drug formulations and a commercially available sustained-release formulation are shown. [Figure 18]The dissolution plots for three delayed-release oral drug formulations are shown. [Figure 19] The mean plasma concentration-time curves after administration of three delayed-release oral drug formulations and commercially available sustained-release formulations are shown. [Figure 20] The dissolution plots for three delayed-release oral drug formulations are shown. [Figure 21] The mean plasma concentration-time curves after administration of two delayed-release oral drug formulations and a commercially available sustained-release formulation are shown. [Figure 22] The mean plasma concentration-time curves after administration of delayed-release oral drug formulations and commercially available sustained-release formulations are shown. [Figure 23] This shows the dissolution plot for delayed-release oral drug formulations. [Modes for carrying out the invention]

[0069] Provided herein are, in some embodiments, delayed-release oral drug formulations of Janus kinase (JAK) inhibitors. In some embodiments, the delayed-release oral drug formulation comprises a JAK inhibitor and a sustained-release drug component comprising a delaying component, which is configured to prevent the release of the JAK inhibitor from the oral drug formulation for a desired time after administration of the delayed-release oral drug formulation to a human subject. In some embodiments, the sustained-release drug component is configured to release the JAK inhibitor according to a desired release profile. In some embodiments, the sustained-release drug component comprises a first corrosive material mixed with the JAK inhibitor, and the release of the JAK inhibitor is based on the corrosion of the first corrosive material.

[0070] The delayed-release oral drug formulations described herein are based, at least in part, on the inventors' unique insights and knowledge regarding the design of such oral drug formulations to improve JAK inhibitor therapy through precision drug release. As discussed above, patients with certain dysfunctional JAK-STAT signaling pathway-related disorders experience severe morning symptoms (or symptoms upon waking from sleep, depending on the individual's sleep schedule). The delayed-release oral drug formulations described herein are designed and configured so that a human individual takes the oral drug formulation near bedtime (e.g., at night), and the oral drug formulation releases the JAK inhibitor during sleep, so that the necessary drug levels to effectively alleviate symptoms are obtained and maintained during this required time, resulting in symptom relief and waking. The delayed-release oral drug formulations described herein provide a convenient method for improving treatment compliance with once-daily administration and improving the individual's quality of life during waking hours.

[0071] Accordingly, in some embodiments, the herein provides a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor, the delayed-release oral drug dosage form comprising a sustained-release drug component comprising a first corrosive material mixed with a JAK inhibitor, and a delaying component, the delaying component preventing the release of the JAK inhibitor from the delayed-release oral drug dosage form for about 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human subject.

[0072] In other embodiments, provided herein is a commercial batch of any one of the delayed-release oral drug dosage forms described herein. In some embodiments, the commercial batch has a standard deviation of about 0.05 or less for one or more of the following: the amount of JAK inhibitor in the delayed-release oral drug dosage form, the weight of the delayed-release oral drug dosage form, the maximum cross-sectional dimension of the delayed-release oral drug dosage form, and the cross-sectional dimension perpendicular to the maximum cross-sectional dimension of the delayed-release oral drug dosage form.

[0073] In other embodiments, provided herein is a method for preparing any one of the delayed-release tofacitinib oral drug dosage forms described herein, the method comprising three-dimensional (3D) printing of the delayed-release tofacitinib oral drug dosage. In some embodiments, the delayed-release tofacitinib oral drug dosage form comprises a sustained-release drug component comprising a first corrosive material mixed with a JAK inhibitor, and a delay member comprising a shell comprising a second corrosive material not mixed with a JAK inhibitor and an isolation material impermeable to body fluids, the method comprising (a) dispensing the sustained-release drug component, (b) dispensing the delay member, and (c) dispensing the shell to form the delayed-release tofacitinib oral drug dosage.

[0074] In other embodiments, the Specified Publicly Provided is a method for preventing morning stiffness caused by rheumatoid arthritis, the method comprising administering to a human individual a delayed-release oral drug formulation described herein, the delayed-release oral drug formulation being administered the night before when an effect is desired to prevent morning stiffness, such as within about one hour before going to bed.

[0075] In other embodiments, the Specified Provision is a method for preventing morning stiffness caused by psoriatic arthritis, comprising administering to a human individual a delayed-release oral drug formulation described herein, the delayed-release oral drug formulation being administered the night before (or on a schedule adjusted based on the individual's observed wakefulness and sleep duration) when it is desired to be effective in preventing morning stiffness, such as within about one hour of going to bed.

[0076] In other embodiments, the foregoing provides a method for treating ulcerative colitis, comprising administering to a human individual a delayed-release oral drug formulation described herein. In some embodiments, the delayed-release oral drug formulation is administered overnight to provide relief of symptoms the following morning.

[0077] I. Definition For the purposes of interpreting this Spec., the following definitions apply, and wherever appropriate, a term used in the singular also includes the plural, and vice versa. In the event of any conflict between any of the following definitions and any document incorporated herein by reference, the following definitions shall prevail.

[0078] As used herein, the term "tofacitinib" includes any pharmaceutically acceptable form and its salts unless otherwise specified. In some embodiments, tofacitinib may exist in crystalline form. In some embodiments, tofacitinib may exist in amorphous form. In some embodiments, a pharmaceutically acceptable form is any pharmaceutically acceptable form, including solvates, hydrates, isomorphs, polymorphs, cocrystals, pseudomorphs, neutral forms, acid-added salt forms, and prodrugs. In some embodiments, a pharmaceutically acceptable form is a pharmaceutically acceptable salt. Conventional concentrations and recrystallization techniques may be employed for the production and isolation of pharmaceutically acceptable salts of JAK inhibitors, including the use of acids such as acetic acid, lactic acid, succinic acid, maleic acid, tartaric acid, citric acid, gluconic acid, ascorbic acid, mesylic acid, tosylic acid, benzoic acid, cinnamic acid, fumaric acid, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfamic acid, methanesulfonic acid, benzenesulfonic acid, and related sulfonic acids. In some embodiments, tofacitinib is tofacitinib citrate.

[0079] As used herein, the terms “treat,” “treatment,” “treating,” or their equivalents refer to an approach to obtain a beneficial or desired outcome, including, for example, the alleviation of symptoms of a disease. For the purposes of this disclosure, a beneficial or desired clinical outcome includes, but is not limited to, one or more of the following: alleviating one or more symptoms of a disease; reducing the severity of one or more symptoms of a disease; preventing an increase in the severity of one or more symptoms of a disease; reducing the dosage of one or more other medicines required to treat and / or manage the disease; and improving quality of life.

[0080] As used herein, the terms “prevent,” “prevention,” or “preventing,” or their equivalents, refer to an approach to obtain a beneficial or desired outcome, including, for example, a reduction in the expected future symptoms of a disease. For the purposes of this disclosure, a beneficial or desired clinical outcome includes, but is not limited to, one or more of the following: preventing the onset and / or increase in the severity of one or more symptoms caused by the disease; alleviating one or more symptoms caused by the disease; reducing the severity of one or more symptoms caused by the disease; reducing the dose of one or more other medicines required to treat and / or manage the disease; and improving quality of life.

[0081] As used herein, the term “individual” refers to mammals, including but not limited to humans, cattle, horses, felines, canines, rodents, rats, mice, dogs, or primates. In some embodiments, the individual is a human individual.

[0082] As used herein, the terms “comprising,” “having,” “containing,” and “including,” as well as other similar forms and their grammatical synonyms, are intended to be semantically equivalent and are intended to be open-ended in that the items or items following any one of these words are not intended to be an exhaustive list of such items or items, nor to be intended to be limited to only the listed items or items. For example, an article “comprising” components A, B, and C may consist of (i.e., consist only of) components A, B, and C, or may contain one or more other components in addition to components A, B, and C. Accordingly, “comprises” and its similar forms, as well as its grammatical synonyms, are intended and understood to include disclosures of embodiments that “essentially consist of” or “consist of.”

[0083] Where a range of values ​​is provided, unless the context clearly indicates otherwise, it is understood that each intervening value up to one-tenth of the lower limit between the upper and lower limits of that range and any other stated or intervening value within that stated range is included in this disclosure, subject to any specifically excluded limits within the stated range. If the stated range includes one or both of the limits, the range excluding one or both of the included limits is also included in the disclosure.

[0084] In this specification, any reference to “about” a value or parameter includes (and describes) variations relating to the value or parameter itself. For example, a statement referring to “about X” includes a statement of “X.”

[0085] As used herein, including in the attached claims, the singular forms "a," "or," and "the" refer to multiple subjects unless the context clearly indicates otherwise.

[0086] II. Delayed-release oral drug dosage forms Provided herein are, in some embodiments, delayed-release oral drug formulations of Janus kinase (JAK) inhibitors. In some embodiments, the delayed-release oral drug formulations described herein comprise a JAK inhibitor and a sustained-release drug component comprising a delaying component, which is configured to prevent the release of the JAK inhibitor from the oral drug formulation for a desired time after administration of the delayed-release oral drug formulation to a human subject. In some embodiments, the sustained-release drug component is configured to release the JAK inhibitor in conjunction with the oral drug formulation or a portion thereof according to a desired release profile. In some embodiments, the oral drug formulation further comprises an immediate-release drug component comprising a JAK inhibitor.

[0087] The oral drug dosage forms disclosed herein may include various combinations of the components described herein and may be arranged in diverse configurations. Such components and configurations for forming delayed-release oral drug dosage forms are configured to achieve a desired delayed-release profile for JAK inhibitors. In some cases, such components and configurations are described in a modular manner, and such descriptions are not intended to limit the scope of oral drug dosage forms included herein.

[0088] A. Components and composition of delayed-release oral drug formulations In some embodiments, the components of the delayed-release oral drug dosage form described herein include a sustained-release drug component containing a JAK inhibitor and a delay component. In some embodiments, the delay component includes a delay member and a shell.

[0089] For illustrative purposes and to facilitate understanding of specific components and their composition, cross-sectional diagrams of exemplary delayed-release oral drug dosage forms described herein are provided in Figures 1A–1H. In some embodiments of this disclosure, as illustrated in Figures 1A–1H, the exemplary delayed-release oral drug dosage form includes a sustained-release drug component comprising a corrosive material mixed with a JAK inhibitor, a delay member comprising a corrosive material not mixed with the JAK inhibitor, and a delay component comprising a shell. The dashed lines in Figures 1A–1H represent portions of one or more components of the delayed-release oral drug dosage form having an undefined shape in the schematic diagram, and such portions of one or more components may be configured to facilitate the release of the JAK inhibitor from the delayed-release oral drug dosage form by reducing the adhesion of the portion of the oral drug dosage form to the inside of the human body, for example, which can prevent or inhibit the release of the JAK inhibitor from the oral drug dosage form to any degree. In some embodiments, such portions of one or more components are not flat.

[0090] Figure 1A provides a cross-sectional view of an exemplary delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor 100, the delayed-release oral drug dosage form 100 comprising a sustained-release drug component comprising a first corrosive material mixed with the JAK inhibitor 105, and a delay component, the delay component comprising a delay member comprising a second corrosive material not mixed with the JAK inhibitor 110, and a shell 115. As shown in Figure 1A, the sustained-release drug component 105 has a top surface 106, a side surface 107, and a bottom surface 108, and the delay member 110 has a top surface 111, a side surface 112, and a bottom surface 113. In some embodiments, the delay component (e.g., the delay member 110 and the shell 115) surrounds the sustained-release drug component 105. The delayed-release oral drug dosage form 100 in Figure 1A is configured such that, upon administration to a human organism and exposure to body fluids, the upper surface 111 of the delay member 110 is first exposed to body fluids and corrodes away from the oral drug dosage form in the direction of arrow 120. As shown in Figure 1B, at some point after administration to a human organism, the upper surface 106 of the sustained-release drug component 105 is exposed to body fluids and corrodes away from the oral drug dosage form 100 in the direction of arrow 121. In some embodiments, the thickness of the sustained-release drug component 105 is measured from the upper surface 106 to the lower surface 108 in a direction substantially parallel to the direction of corrosion 121 of the sustained-release drug component. For example, as shown in Figure 1B, the thickness of the sustained-release drug component 105 is indicated by marker 125.

[0091] As disclosed herein, the components of a delayed-release oral drug dosage form may consist of a number of shapes and sizes. Unless otherwise specified, references to specific shapes, sizes, and measurements reflect the delayed-release oral drug dosage form before administration to a human organism, for example, before the corrosion of any of its components.

[0092] i. Sustained-release drug components The delayed-release oral drug dosage forms disclosed herein include a sustained-release drug component containing a JAK inhibitor. In some embodiments, the sustained-release drug component includes a corrosive material containing a JAK inhibitor. The sustained-release drug component can be formed using a number of materials having various shapes and sizes (including materials having various JAK inhibitor drug mass fractions).

[0093] In some embodiments, the sustained-release drug component is a layer. In some embodiments, the sustained-release drug component comprises a plurality of beads.

[0094] In some embodiments, the sustained-release drug component is configured to have a surface such as a surface that is exposed to body fluid during administration of an oral drug dosage form to a human individual, having a predetermined shape and surface area. For example, in some embodiments, the sustained-release drug component has a top surface and a bottom surface, and the top surface is exposed to body fluid before the bottom surface. In some embodiments, the sustained-release drug component is a layer having a top surface and a bottom surface. In some embodiments, the top surface of the sustained-release drug component is not flat and includes certain features that extend beyond a top surface plane or a surface tolerance threshold (measured between two parallel planes), such as reducing the adhesion of the sustained-release drug layer or a portion thereof to the interior of the human individual. In some embodiments, the top surface of the sustained-release drug component, or at least a portion thereof, is flat or within a surface tolerance threshold.

[0095] The top surface of the sustained-release drug component can have any shape with reference to the surface exposed to body fluid. In some embodiments, the top surface of the sustained-release drug component has a shape of a capsule, a circle, an ellipse, a bullet shape, an arrowhead shape, a triangle, an arc triangle, a square, an arc square, a rectangle, an arc rectangle, a diamond, a pentagon, a hexagon, an octagon, a half moon, an almond, or a combination thereof with reference to the surface exposed to body fluid. <00​​​​​​​​​​​​​​​​​​​​​​​​​2 , 26mm 2 , 28mm 2 , 30mm 2 , 32mm 2 ,33mm 2 , 34mm 2 , 36mm 2 , 38mm 2 , 40mm 2 , 42mm 2 , 44mm 2 , 46mm 2 , 48mm 2 , 50mm 2 , 52mm 2 , 54mm 2 , 56mm 2 , 58mm 2 , 60mm 2 , 65mm 2 , 70mm 2 , 80mm 2 , 85mm 2 , 90mm 2 , 95mm 2 , 100mm 2 , 110mm 2 , 120mm 2 , 130mm 2 , 140mm 2 , 150mm 2 , 160mm 2 , 170mm 2 , 180mm 2 , 190mm 2 , 200mm 2 , 225mm 2 , 250mm 2 , 275mm 2 , 300mm 2 , 325mm 2 , 350mm 2 , 375mm 2 , or 400mm 2 One of the following, at least approximately 20mm 2 It has a surface area of ​​approximately 400 mm. In some embodiments, the upper surface of the sustained-release drug component is approximately 400 mm. 2 , 375mm 2 , 350mm 2 , 325mm 2 , 300mm 2 , 275mm 2, 250 mm, 2 , 225 mm, 2 , 200 mm, 2 , 190 mm, 2 , 180 mm, 2 , 170 mm, 2 , 160 mm, 2 , 150 mm, 2 , 140 mm, 2 , 130 mm, 2 , 120 mm, 2 , 110 mm, 2 , 100 mm, 2 , 95 mm, 2 , 90 mm, 2 , 85 mm, 2 , 80 mm, 2 , 75 mm, 2 , 70 mm, 2 , 65 mm, 2 , 60 mm, 2 , 58 mm, 2 , 56 mm, 2 , 54 mm, 2 , 52 mm, 2 , 50 mm, 2 , 48 mm, 2 , 46 mm, 2 , 44 mm, 2 , 42 mm, 2 , 四十毫米, 2 , 38 mm, 2 , 36 mm, 2 , 34 mm, 2 , 32 mm, 2 , 30 mm, 2 , 28 mm, 2 , 26 mm, 2 , 24 mm, 2 , 22 mm, 2 or less than 20 mm, 2 such as less than any of them, having a surface area of less than about 400 mm, 2 In some embodiments, the upper surface of the sustained-release drug component is about 20 mm, 2 , 21 mm, 2 , 22 mm, 2 , 23 mm, 2 , 24 mm, 2 , 25 mm, 2 , 26 mm, 2 , 27 mm, 2 , 28 mm, 2 , 29 mm, 2 , 30 mm2 、31mm 2 、32mm 2 、33mm 2 、34mm 2 、35mm 2 、36mm 2 、37mm 2 、38mm 2 、39mm 2 、40mm 2 、41mm 2 、42mm 2 、43mm 2 、44mm 2 、45mm 2 、46mm 2 、47mm 2 、48mm 2 、49mm 2 、50mm 2 、51mm 2 、52mm 2 、53mm 2 、54mm 2 、55mm 2 、56mm 2 、57mm 2 、58mm 2 、59mm 2 、60mm 2 、65mm 2 、70mm 2 、80mm 2 、85mm 2 、90mm 2 、95mm 2 、100mm 2 、110mm 2 、120mm 2 、130mm 2 、140mm 2 、150mm 2 、160mm 2 、170mm 2 、180mm 2 、190mm 2 、200mm 2 、225mm 2 、250mm 2 、275mm 2 、300mm 2 、325mm 2 、350mm 2 、375mm 2, or 400mm 2 It has one of the following surface areas.

[0097] In some embodiments, the surface area of ​​the top surface of a sustained-release drug component exposed to body fluids is consistent throughout the thickness of the sustained-release drug component; for example, the surface exposed to body fluids has the same surface area as the sustained-release drug component corrodes. In some embodiments, the surface area of ​​the top surface of a sustained-release drug component exposed to body fluids differs in two or more respects; for example, the surface exposed to body fluids changes, such as the surface area increasing and / or decreasing during the corrosion of the sustained-release drug component. In some embodiments, the shape of the surface of a sustained-release drug component exposed to body fluids is consistent throughout the thickness of the sustained-release drug component; for example, the surface exposed to body fluids has the same shape as the sustained-release drug component corrodes. In some embodiments, the shape of the surface of a sustained-release drug component exposed to body fluids differs in two or more respects. In some embodiments, the bottom surface of the sustained-release drug component has the same surface area as the top surface of the sustained-release drug component. In some embodiments, the bottom surface of the sustained-release drug component has a different surface area than the top surface of the sustained-release drug component.

[0098] In some embodiments, the top surface of a sustained-release drug component, such as a sustained-release drug layer, has a maximum cross-sectional dimension of approximately 5 mm to approximately 20 mm, such as approximately 5 mm to approximately 15 mm, approximately 6 mm to approximately 13 mm, or approximately 7 mm to approximately 11 mm. In some embodiments, the top surface of a sustained-release drug component has a maximum cross-sectional dimension of at least approximately 5 mm, such as at least approximately 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the top surface of a sustained-release drug component has a maximum cross-sectional dimension of less than approximately 20 mm, such as less than approximately 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the top surface of the sustained-release drug component has a maximum transverse dimension of approximately 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm.

[0099] In some embodiments, the upper surface of a sustained-release drug component, such as a sustained-release drug layer, has a transverse dimension perpendicular to the maximum transverse dimension, such as approximately 1 mm to approximately 15 mm, approximately 2 mm to approximately 6 mm, or approximately 1 mm to approximately 5 mm. In some embodiments, the upper surface of a sustained-release drug component has a transverse dimension perpendicular to the maximum transverse dimension, such as at least approximately 1 mm, such as at least approximately 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, or 15 mm. In some embodiments, the upper surface of a sustained-release drug component has a transverse dimension perpendicular to the maximum transverse dimension of less than approximately 15 mm, such as less than approximately 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, 5 mm, 4 mm, 3 mm, 2 mm, or 1 mm. In some embodiments, the upper surface of the sustained-release drug component has a transverse dimension perpendicular to the maximum transverse dimension, which is approximately 1 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, or 15 mm.

[0100] In some embodiments, the sustained-release drug component, such as the sustained-release drug component layer, has a thickness of approximately 0.1 mm to approximately 5 mm, such as approximately 0.2 mm to approximately 2 mm, approximately 0.5 mm to approximately 1.5 mm, or approximately 0.8 mm to approximately 1.4 mm. In some embodiments, the sustained-release drug component has a thickness of at least about 0.1 mm, such as at least about 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.2 mm, 2.4 mm, 2.6 mm, 2.8 mm, 3.0 mm, 3.2 mm, 3.4 mm, 3.6 mm, 3.8 mm, 4.0 mm, 4.2 mm, 4.4 mm, 4.6 mm, 4.8 mm, or 5 mm. In some embodiments, the sustained-release drug component has a thickness of less than approximately 5 mm, such as less than 4.8 mm, 4.6 mm, 4.4 mm, 4.2 mm, 4.0 mm, 3.8 mm, 3.6 mm, 3.4 mm, 3.2 mm, 3.0 mm, 2.8 mm, 2.6 mm, 2.4 mm, 2.2 mm, 2.0 mm, 1.9 mm, 1.8 mm, 1.7 mm, 1.6 mm, 1.5 mm, 1.4 mm, 1.3 mm, 1.2 mm, 1.1 mm, 1.0 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm, or 0.1 mm. In some embodiments, the sustained-release drug component has a thickness of approximately 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.2 mm, 2.4 mm, 2.6 mm, 2.8 mm, 3.0 mm, 3.2 mm, 3.4 mm, 3.6 mm, 3.8 mm, 4.0 mm, 4.2 mm, 4.4 mm, 4.6 mm, 4.8 mm, or 5 mm.

[0101] In some embodiments, the sustained-release drug component, such as a sustained-release drug layer, includes a top and a bottom surface, and the thickness measured between the top and bottom surfaces is substantially consistent, such as being within 20% of the average thickness.

[0102] In some embodiments, the sustained-release drug component, such as a sustained-release drug layer, includes sides.

[0103] In some embodiments, the sustained-release drug component is approximately 0.1 to 0.6 of the drug mass fraction (m) of the JAK inhibitor, such as approximately 0.2 to approximately 0.5 or approximately 0.3 to approximately 0.4. F ) has. In some embodiments, the sustained-release drug component has at least about 0.1 drug mass fraction (m) of the JAK inhibitor, such as at least about 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, or 0.6. F ) has. In some embodiments, the sustained-release drug component has a drug mass fraction (m) of the JAK inhibitor less than about 0.6, such as less than about 0.55, 0.5, 0.45, 0.4, 0.35, 0.3, 0.25, 0.2, 0.15, or 0.1. F ) has. In some embodiments, the sustained-release drug component has a drug mass fraction (m) of any of the JAK inhibitors, which is about 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, or 0.6. F ) has.

[0104] In some embodiments, the sustained-release drug component comprises a corrosive material containing a JAK inhibitor. In some embodiments, the release of the JAK inhibitor from the delayed-release oral drug dosage form is based on the corrosion of the sustained-release drug component. In some embodiments, the sustained-release drug component, upon contact with bodily fluids in a human organism, completely corrodes over a period of about 3 to 12 hours, such as about 4 to 8 hours, or about 6 to 10 hours. In some embodiments, the sustained-release drug component, upon contact with bodily fluids in a human organism, completely corrodes over a period of at least about 3 hours, such as at least about 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours. In some embodiments, the sustained-release drug component, upon contact with bodily fluids in a human organism, completely corrodes over a period of less than 12 hours, such as less than 11, 10, 9, 8, 7, 6, 5, 4, or 3 hours. In some embodiments, when the sustained-release drug component comes into contact with bodily fluids within a human body, it completely corrodes over a period of approximately 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours.

[0105] In some embodiments, the amount of JAK inhibitor in the sustained-release drug component is approximately 1 mg to approximately 50 mg, such as approximately 1 mg to approximately 25 mg, approximately 10 mg to approximately 40 mg, approximately 10 mg to approximately 30 mg, approximately 9 mg to approximately 12 mg, approximately 10 mg to approximately 12 mg, approximately 19 mg to approximately 23 mg, or approximately 21 mg to approximately 23 mg. In some embodiments, the amount of JAK inhibitor in the sustained-release drug component is approximately 1 mg or more, such as approximately 3 mg or more, 4 mg or more, 5 mg or more, 6 mg or more, 7 mg or more, 8 mg or more, 9 mg or more, 10 mg or more, 11 mg or more, 12 mg or more, 13 mg or more, 14 mg or more, 15 mg or more, 16 mg or more, 17 mg or more, 18 mg or more, 19 mg or more, 20 mg or more, 21 mg or more, 22 mg or more, 23 mg or more, 24 mg or more, or 25 mg or more. In some embodiments, the amount of JAK inhibitor in the sustained-release drug component is approximately 25 mg or less, such as 24 mg or less, 23 mg or less, 22 mg or less, 21 mg or less, 20 mg or less, 19 mg or less, 18 mg or less, 17 mg or less, 16 mg or less, 15 mg or less, 14 mg or less, 13 mg or less, 12 mg or less, 11 mg or less, 10 mg or less, 9 mg or less, 8 mg or less, 7 mg or less, 6 mg or less, 5 mg or less, 4 mg or less, or 3 mg or less. In some embodiments, the amount of JAK inhibitor in the sustained-release drug component is approximately 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, or 25 mg.

[0106] In some embodiments, the amount of JAK inhibitor in the sustained-release drug component is approximately 11 mg.

[0107] In some embodiments, the amount of JAK inhibitor in the sustained-release drug component is approximately 22 mg.

[0108] In some embodiments, the sustained-release drug component comprises a thermoplastic material, such as a thermoplastic polymer. In some embodiments, the sustained-release drug component comprises a material comprising a corrosive thermoplastic material such as a sustained-release corrosive material or an immediate-release corrosive material, a drug diffusion material, a plasticizer, and one or more other additives, such as fillers, binders, lubricants, flow enhancers, and disintegrants.

[0109] In some embodiments, the corrosive thermoplastic material is polyvinylpyrrolidone-co-vinyl acetate (PVP-VA), polyvinylpyrrolidone-polyvinyl acetate copolymer (PVP-VA) 60 / 40, polyvinylpyrrolidone (PVP), polyethylene oxide (PEO), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57 / 30 / 13, aminoalkyl methacrylate copolymer E, hydroxypropyl methylcellulose acetate succinate or hypromellose acetate succinate (HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP), copolyvidone, hydroxypropyl methylcellulose This material contains one or more of the following: lurose (HPC), hydroxypropyl methylcellulose or hypromellose (HPMC), methylcellulose (MC), methacrylic acid copolymer, poly(dimethylaminoethyl methacrylate-co-methacrylate ester), poly(ethyl acrylate-co-methacrylate-co-trimethylammonioethyl methacrylate chloride), poly(methyl acrylate-co-methacrylate-co-methacrylate) 7:3:1, poly(methacrylate-co-methacrylate methyl) 1:2, poly(methacrylate-co-acrylate ethyl) 1:1, poly(methacrylate-co-methyl methacrylate) 1:1, polyethylene glycol-polyvinyl alcohol graft copolymer 25 / 75, Kollicoat IR-polyvinyl alcohol 60 / 40, methacrylic acid ester copolymer, and ammoniaalkyl methacrylate copolymer.

[0110] In some embodiments, the sustained-release corrosive material is copolyvidone, polyvinylpyrrolidone-co-vinyl acetate (PVP-VA), polyvinylpyrrolidone-polyvinyl acetate copolymer (PVP-VA) 60 / 40, polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose or hypromelose (HPMC), hydroxypropyl methylcellulose phthalate (HPMCP), methylcellulose (MC), methacrylic acid copolymer, poly(dimethylaminomethyl acrylate-co-ethylacrylate), poly(ethyl acrylate-co-methylmethacrylate) (T-co-trimethylammonium ethyl methacrylate), poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:1, polyethylene oxide (PEO), polyethylene glycol (PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57 / 30 / 13, polyethylene glycol-polyvinyl alcohol graft copolymer 25 / 75, Kollicoat IR-Polyvinyl alcohol 60 / 40. Contains one or more of the following: polyvinyl alcohol (PVA), aminoalkyl methacrylate copolymer E, hydroxypropyl methylcellulose acetate succinate or hypromellose acetate succinate (HPMCAS), methacrylate copolymer, glycerol, and ammoniaalkyl methacrylate copolymer.

[0111] In some embodiments, the immediately released corrosive thermoplastic material is copolyvidone, polyvinylpyrrolidone-co-vinyl acetate (PVP-VA), polyvinylpyrrolidone-polyvinyl acetate copolymer (PVP-VA) 60 / 40, polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose or hypromellose (HPMC), hydroxypropyl methylcellulose phthalate (HPMCP), methylcellulose (MC), methacrylic acid copolymer, poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1, poly(dimethylaminoethyl methacrylate-co-methacrylate) Poly(ethyl acrylate-co-methacrylate-co-trimethylammoniumethyl methacrylate chloride), poly(methyl acrylate-co-methacrylate-co-methacrylate) 7:3:1, poly(methacrylate-co-methyl methacrylate) 1:2, poly(methacrylate-co-ethyl acrylate) 1:1, poly(methacrylate-co-methyl methacrylate) 1:1, polyethylene oxide (PEO), polyethylene glycol (PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57 / 30 / 13, polyethylene glycol-polyvinyl alcohol graft copolymer 25 / 75, Kollicoat This product contains one or more of the following: IR-polyvinyl alcohol 60 / 40, polyvinyl alcohol (PVA), aminoalkyl methacrylate copolymer E, hydroxypropyl methylcellulose acetate succinate or hypromellose acetate succinate (HPMCAS), methacrylate copolymer, ammoniaalkyl methacrylate copolymer, ethylcellulose (EC), polyvinyl acetate (PVAc) and polyvinylpyrrolidone (PVP) 80 / 20, polyvinyl acetal diethylaminolactic acid, and polyvinyl acetal diethylaminolactic acid (AEA).

[0112] In some embodiments, the drug diffusion material includes a swellable polymer impregnated with a drug, for example, so that the drug is released from the drug diffusion material upon swelling. In some embodiments, the drug diffusion material includes one or more of the following: cellulose acetate phthalate (CAP), methacrylate ammonia copolymer, poly(lactide-co-glycolide) (PLGA), ethylene-vinyl acetate copolymer, polyethylene (PE), polycaprolactone (PCL), polylactic acid (PLA), eryllulose butyrate acetate (CAB), cellulose acetate (CA), polyvinyl acetate (PVAc), polyvinyl acetal diethylaminolactic acid (AEA), poly(butyl methacrylate-co-(2-dimethylamino)methacrylate-co-methylacrylate) 1:2:1, ethylcellulose (EC), polyvinyl acetate (PVAc), polyvinylpyrrolidone (PVP) (80 / 20), and crospovidone.

[0113] In some embodiments, the plasticizer comprises one or more of the following: triethyl citrate (TEC), vitamin e succinate polyethylene glycol salt (TPGS), acetin, triethyl acetyl citrate, tributyl citrate, tributyl o-acetyl citrate, polyoxy-15 hydroxystearate, PEG-40 hydrogenated castor oil, polyoxy-35 castor oil, dibutyl sebacate, diethyl phthalate, glycerin, methyl 4-hydroxybenzoate, castor oil, oleic acid, triacetin, and polyalkylene glycol.

[0114] In some embodiments, other additives include acacia, alginate, alginic acid, aluminum acetate, butylparaben, butylated hydroxytoluene, citric acid, calcium carbonate, candelilla wax, croscarmellose sodium, powdered sugar, colloidal silicone dioxide, cellulose, simple or anhydrous calcium phosphate, carnuba wax, corn starch, carboxymethylcellulose calcium, calcium disodium ethylenediaminetetraacetic acid (EDTA), calcium hydrogen phosphate dehydrated, cetylpyridine chloride, dicalcium phosphate, tribasic calcium phosphate, dicalcium phosphate, disodium hydrogen phosphate, dimethicone, sodium erythrosine, ethylenediaminetetraacetic acid (EDTA), gelatin, glyceryl monooleate, iron oxide, ferrous oxide, yellow iron oxide, red iron oxide, lactose (hydrate) Contains one or more of the following (anhydrous, monohydrate, or spray-dried), microcrystalline cellulose, magnesium carbonate, magnesium oxide, methylparaben, polysorbate 80, propyleneparaben, potassium bicarbonate, potassium sorbate, potato starch, phosphoric acid, polyoxyethylene (40) stearate, sodium starch glycolate, pregelled starch, crosmellose sodium, sodium lauryl sulfate, starch, silicon dioxide, sodium benzoate, sucrose, sorbic acid, sodium carbonate, sodium saccharin, sodium alginate, silica gel, sorbitan monooleate, sodium chloride, sodium metabisulfite, dehydrated sodium citrate, sodium starch, sodium carboxymethylcellulose, succinic acid, sodium propionate, titanium dioxide, and talc.

[0115] In some embodiments, the sustained-release oral drug dosage form comprises one or more of hydroxypropyl cellulose (HPC EF), vinylpyrrolidone-vinyl acetate copolymer (e.g., VA64 or copovidone), triethyl citrate (TEC), and glycerin. In some embodiments, the sustained-release oral drug dosage form comprises about 35 w / w% to about 45 w / w% of HPC EF, about 5 w / w% to about 15 w / w% of VA64, and about 10 w / w% to about 20 w / w% of glycerin.

[0116] ii. Delayed component The delayed-release oral drug formulations described herein include a delay component configured to prevent and / or inhibit the release of a JAK inhibitor from the oral drug formulation for a desired period of time after administration of the delayed-release oral drug formulation to a human organism.

[0117] In some embodiments, the delay component does not include a JAK inhibitor.

[0118] In some embodiments, the delaying component surrounds the sustained-release drug component. In some embodiments, the delaying component completely surrounds the sustained-release drug component.

[0119] In some embodiments, the delaying component includes a corrosive material. In some embodiments, the corrosive material of the delaying component is different from the corrosive material of the sustained-release drug component. In some embodiments, the delaying component includes a delaying member comprising a second corrosive material not mixed with the JAK inhibitor, and a shell. In some embodiments, the delaying member and the shell surround the sustained-release drug component, such as completely surrounding it.

[0120] iii. Delay member The retarding members described herein include corrosive materials that are not mixed with the JAK inhibitor. The retarding members can be formed using a number of materials having various shapes and sizes. In some embodiments, the retarding member is a layer.

[0121] In some embodiments, the delay member is configured to have a surface having a predetermined shape and surface area, such as a surface exposed to body fluids during the administration of an oral drug dosage form to a human individual. For example, in some embodiments, the delay member has a top surface and a bottom surface, the top surface being exposed to body fluids before the bottom surface. In some embodiments, the delay member is a layer having a top surface and a bottom surface. In some embodiments, the top surface of the delay member is not flat and includes certain features that extend beyond the top surface plane or a surface tolerance threshold (measured between two parallel planes), for example, to reduce adhesion of the delay member or a portion thereof to the body of a human individual. In some embodiments, the top surface of the delay member, or at least a portion thereof, is flat or within a surface tolerance threshold.

[0122] The upper surface of the delay member can have any shape relative to the surface exposed to the bodily fluids. In some embodiments, the upper surface of the delay member can have the shape of a capsule, circle, ellipse, bullet shape, arrowhead shape, triangle, arc-triangle, square, arc-square, rectangle, arc-rectangle, diamond, pentagon, hexagon, octagon, crescent, almond, or a combination thereof, relative to the surface exposed to the bodily fluids.

[0123] In some embodiments, the upper surface of a delay member, such as a delay member layer, is approximately 20 mm 2 ~about 200mm 2 , about 20mm 2 ~approximately 100mm 2 , about 20mm 2 ~about 60mm 2 , about 30mm 2 ~approximately 50mm 2 Approximately 10mm, including one of the following: 2 ~400mm 2 It has a surface area of ​​at least about 22 mm. In some embodiments, the upper surface of the delay member has a surface area of ​​at least about 22 mm. 2 , 24mm 2 , 26mm 2 , 28mm 2 , 30mm 2 , 32mm 2 ,33mm 2 , 34mm 2 , 36mm2 , 38mm 2 , 40mm 2 , 42mm 2 , 44mm 2 , 46mm 2 , 48mm 2 , 50mm 2 , 52mm 2 , 54mm 2 , 56mm 2 , 58mm 2 , 60mm 2 , 65mm 2 , 70mm 2 , 80mm 2 , 85mm 2 , 90mm 2 , 95mm 2 , 100mm 2 , 110mm 2 , 120mm 2 , 130mm 2 , 140mm 2 , 150mm 2 , 160mm 2 , 170mm 2 , 180mm 2 , 190mm 2 , 200mm 2 , 225mm 2 , 250mm 2 , 275mm 2 , 300mm 2 , 325mm 2 , 350mm 2 , 375mm 2 , or 400mm 2 One of the following, at least approximately 20mm 2 It has a surface area of ​​approximately 400 mm. In some embodiments, the upper surface of the delay member is approximately 400 mm 2 , 375mm 2 , 350mm 2 , 325mm 2 , 300mm 2 , 275mm 2 , 250mm 2 , 225mm 2 , 200mm 2 , 190mm 2 , 180mm 2 , 170mm 2 , 160mm2 , 150mm 2 , 140mm 2 , 130mm 2 , 120mm 2 , 110mm 2 , 100mm 2 , 95mm 2 , 90mm 2 , 85mm 2 , 80mm 2 , 75mm 2 , 70mm 2 , 65mm 2 , 60mm 2 , 58mm 2 , 56mm 2 , 54mm 2 , 52mm 2 , 50mm 2 , 48mm 2 , 46mm 2 , 44mm 2 , 42mm 2 , 40mm 2 , 38mm 2 , 36mm 2 , 34mm 2 , 32mm 2 , 30mm 2 , 28mm 2 , 26mm 2 , 24mm 2 , 22mm 2 or 20mm 2 Approximately 400mm, less than either of the following: 2 It has a surface area of ​​less than 20 mm. In some embodiments, the upper surface of the delay member is about 20 mm 2 , 21mm 2 , 22mm 2 , 23mm 2 , 24mm 2 , 25mm 2 , 26mm 2 , 27mm 2 , 28mm 2 , 29mm 2 , 30mm 2 , 31mm 2 , 32mm 2 ,33mm 2 , 34mm 2 , 35mm 2 , 36mm 2, 37mm 2 , 38mm 2 , 39mm 2 , 40mm 2 , 41mm 2 , 42mm 2 , 43mm 2 , 44mm 2 , 45mm 2 , 46mm 2 , 47mm 2 , 48mm 2 , 49mm 2 , 50mm 2 , 51mm 2 , 52mm 2 , 53mm 2 , 54mm 2 , 55mm 2 , 56mm 2 , 57mm 2 , 58mm 2 , 59mm 2 , 60mm 2 , 65mm 2 , 70mm 2 , 80mm 2 , 85mm 2 , 90mm 2 , 95mm 2 , 100mm 2 , 110mm 2 , 120mm 2 , 130mm 2 , 140mm 2 , 150mm 2 , 160mm 2 , 170mm 2 , 180mm 2 , 190mm 2 , 200mm 2 , 225mm 2 , 250mm 2 , 275mm 2 , 300mm 2 , 325mm 2 , 350mm 2 , 375mm 2 , or 400mm 2 It has one of the following surface areas.

[0124] In some embodiments, the surface area of ​​the upper surface of the delay member exposed to bodily fluids is consistent throughout the thickness of the delay member, for example, the surface exposed to bodily fluids has the same surface area as the delay member corrodes. In some embodiments, the surface area of ​​the upper surface of the delay member exposed to bodily fluids differs in two or more points, for example, the surface exposed to bodily fluids changes, such as the surface area increasing and / or decreasing during the corrosion of the delay member. In some embodiments, the shape of the surface of the delay member exposed to bodily fluids is consistent throughout the thickness of the delay member, for example, the surface exposed to bodily fluids has the same surface area as the delay member corrodes. In some embodiments, the shape of the surface of the delay member exposed to bodily fluids differs in two or more points. In some embodiments, the bottom surface of the delay member has the same surface area as the upper surface of the delay member. In some embodiments, the bottom surface of the delay member has a different surface area than the upper surface of the delay member.

[0125] In some embodiments, the top surface of the delay member has a maximum cross-sectional dimension of approximately 5 mm to approximately 20 mm, such as approximately 5 mm to approximately 15 mm, approximately 6 mm to approximately 13 mm, or approximately 7 mm to approximately 11 mm. In some embodiments, the top surface of the delay member has a maximum cross-sectional dimension of at least approximately 5 mm, such as at least approximately 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the top surface of the delay member has a maximum cross-sectional dimension of less than approximately 20 mm, such as less than approximately 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the upper surface of the delay member has a maximum transverse dimension of approximately 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm.

[0126] In some embodiments, the upper surface of a delay member, such as a delay member layer, has a transverse dimension perpendicular to the maximum transverse dimension, ranging from approximately 1 mm to approximately 15 mm, such as approximately 2 mm to approximately 10 mm, approximately 2 mm to approximately 6 mm, or approximately 1 mm to approximately 5 mm. In some embodiments, the upper surface of a delay member has a transverse dimension perpendicular to the maximum transverse dimension, ranging from at least approximately 1 mm, such as at least approximately 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, or 15 mm. In some embodiments, the upper surface of a delay member has a transverse dimension perpendicular to the maximum transverse dimension of less than approximately 15 mm, such as less than approximately 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, 5 mm, 4 mm, 3 mm, 2 mm, or 1 mm. In some embodiments, the upper surface of the delay member has a transverse dimension perpendicular to the maximum transverse dimension, which is approximately 1 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, or 15 mm.

[0127] In some embodiments, the delay member, such as a delay member layer, has a thickness of about 0.1 mm to about 5 mm, such as about 0.2 mm to about 2 mm, about 0.5 mm to about 1.5 mm, or about 0.8 mm to about 1.4 mm. In some embodiments, the delay member has a thickness of at least about 0.1 mm, such as at least about 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.2 mm, 2.4 mm, 2.6 mm, 2.8 mm, 3.0 mm, 3.2 mm, 3.4 mm, 3.6 mm, 3.8 mm, 4.0 mm, 4.2 mm, 4.4 mm, 4.6 mm, 4.8 mm, or 5 mm. In some embodiments, the delay member has a thickness of less than approximately 5 mm, such as less than 4.8 mm, 4.6 mm, 4.4 mm, 4.2 mm, 4.0 mm, 3.8 mm, 3.6 mm, 3.4 mm, 3.2 mm, 3.0 mm, 2.8 mm, 2.6 mm, 2.4 mm, 2.2 mm, 2.0 mm, 1.9 mm, 1.8 mm, 1.7 mm, 1.6 mm, 1.5 mm, 1.4 mm, 1.3 mm, 1.2 mm, 1.1 mm, 1.0 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm, or 0.1 mm. In some embodiments, the delay member has a thickness of approximately 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.2 mm, 2.4 mm, 2.6 mm, 2.8 mm, 3.0 mm, 3.2 mm, 3.4 mm, 3.6 mm, 3.8 mm, 4.0 mm, 4.2 mm, 4.4 mm, 4.6 mm, 4.8 mm, or 5 mm.

[0128] In some embodiments, the delay member, such as a delay member layer, includes a top surface and a bottom surface, and the thickness measured between the top and bottom surfaces is substantially consistent, such as being within 20% of the average thickness.

[0129] In some embodiments, the delay member, such as a delay member layer, includes sides.

[0130] In some embodiments, the retarder comprises a corrosive material not mixed with the JAK inhibitor. In some embodiments, the retarder, such as the corrosive material of the retarder, comprises a thermoplastic material, such as a thermoplastic polymer. In some embodiments, the retarder comprises a plasticizer and another additive, such as one or more of fillers, binders, lubricants, flow enhancers, and disintegrants.

[0131] In some embodiments, the corrosive thermoplastic material is copolyvidone, polyvinylpyrrolidone-co-vinyl acetate (PVP-VA), polyvinylpyrrolidone-polyvinyl acetate copolymer (PVP-VA) 60 / 40, polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose or hypromellose (HPMC), hydroxypropyl methylcellulose phthalate (HPMCP), methylcellulose (MC), methacrylic acid copolymer, poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1, poly(dimethylaminoethyl methacrylate-co-methacrylic acid Poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonium ethyl methacrylate chloride), poly(methyl acrylate-co-methyl methacrylate-co-methacrylate) 7:3:1, poly(methacrylate-co-methyl methacrylate) 1:2, poly(methacrylate-co-ethyl acrylate) 1:1, poly(methacrylate-co-methyl methacrylate) 1:1, polyethylene oxide (PEO), polyethylene glycol (PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57 / 30 / 13, polyethylene glycol-polyvinyl alcohol graft copolymer 25 / 75, Kollicoat It contains one or more of the following: IR-polyvinyl alcohol 60 / 40, polyvinyl alcohol (PVA), aminoalkyl methacrylate copolymer E, hydroxypropyl methylcellulose acetate succinate or hypromellose acetate succinate (HPMCAS), methacrylate ester copolymer, ammoniaalkyl methacrylate copolymer, ethylcellulose (EC), polyvinyl acetal diethylaminolactic acid, and polyvinyl acetal diethylaminolactic acid (AEA).

[0132] In some embodiments, the plasticizer comprises one or more of the following: triethyl citrate (TEC), vitamin E polyethylene glycol succinate (TPGS), acetin, triethyl acetyl citrate, tributyl citrate, tributyl o-acetyl citrate, polyoxy-15 hydroxystearate, PEG-40 hydrogenated castor oil, polyoxy-35 castor oil, dibutyl sebacate, diethyl phthalate, glycerin, methyl 4-hydroxybenzoate, castor oil, oleic acid, triacetin, and polyalkylene glycol.

[0133] In some embodiments, other additives include acacia, alginate, alginic acid, aluminum acetate, barium sulfate, butylparaben, butylated hydroxytoluene, citric acid, calcium carbonate, calcium superphosphate, candelilla wax, croscarmellose sodium, powdered sugar, colloidal silicone dioxide, cellulose, simple or anhydrous calcium phosphate, carnuba wax, corn starch, carboxymethylcellulose calcium, calcium disodium ethylenediaminetetraacetic acid (EDTA), calcium hydrogen phosphate dehydrated, cetylpyridine chloride, dicalcium phosphate, tribasic calcium phosphate, dicalcium phosphate, disodium hydrogen phosphate, dimethicone, sodium erythrosine, ethylenediaminetetraacetic acid (EDTA), gelatin, glycerol, glyceryl monooleate, iron oxide, ferrous oxide, yellow iron oxide, red iron oxide, L1 00-55 contains one or more of the following: lactose (hydrate, anhydrous, monohydrate, or spray-dried), microcrystalline cellulose, magnesium carbonate, magnesium oxide, methylparaben, polysorbate 80, propyleneparaben, potassium bicarbonate, potassium sorbate, potato starch, phosphoric acid, polyoxyethylene (40) stearate, sodium starch glycolate, pregelled starch, sodium crosmellose, sodium lauryl sulfate, starch, silicon dioxide, sodium benzoate, sucrose, sorbic acid, sodium carbonate, sodium saccharin, sodium alginate, silica gel, sorbitan monooleate, sodium chloride, sodium metabisulfite, dehydrated sodium citrate, sodium starch, sodium carboxymethylcellulose, succinic acid, sodium propionate, titanium dioxide, and talc.

[0134] In some embodiments, the retarder comprises one or more of hydroxypropyl cellulose (HPC EF), triethyl citrate (TEC), and titanium dioxide. In some embodiments, the retarder comprises about 80 w / w% to about 90 w / w% of HPC EF, about 10 w / w% to about 20 w / w% of TEC, and about 0.1 w / w% to about 0.3 w / w% of titanium dioxide.

[0135] iv. Shell In some embodiments, the delay component includes a shell. In some embodiments, the shell is configured to have a surface, such as an outer surface, that is exposed to body fluids during administration of the oral drug dosage form to a human organism. In some embodiments, the outer surface of the shell is not flat and includes certain features that extend beyond a surface plane or surface tolerance threshold (measured between two parallel planes), for example, to reduce adhesion of the shell or a portion thereof to the inside of a human organism's body. In some embodiments, the outer surface of the shell, or at least a portion thereof, is flat or within a surface tolerance threshold.

[0136] The surface of the shell can have any shape relative to the surface exposed to bodily fluids. In some embodiments, the surface of the shell can have the shape of a capsule, circle, ellipse, bullet shape, arrowhead shape, triangle, arc-triangle, square, arc-square, rectangle, arc-rectangle, diamond, pentagon, hexagon, octagon, crescent, almond, or a combination thereof, relative to the surface exposed to bodily fluids.

[0137] In some embodiments, the shell has a maximum cross-sectional dimension of approximately 5 mm to approximately 20 mm, such as approximately 5 mm to approximately 15 mm, approximately 6 mm to approximately 13 mm, or approximately 7 mm to approximately 11 mm. In some embodiments, the shell has a maximum cross-sectional dimension of at least approximately 5 mm, such as at least approximately 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the shell has a maximum cross-sectional dimension of less than approximately 20 mm, such as less than approximately 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the shell has a maximum transverse dimension of approximately 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the maximum transverse dimension is measured across the surface of the delayed-release oral drug dosage form.

[0138] In some embodiments, the shell has a transverse dimension perpendicular to a maximum transverse dimension of approximately 5 mm to approximately 20 mm, such as approximately 5 mm to approximately 15 mm, approximately 6 mm to approximately 13 mm, or approximately 7 mm to approximately 11 mm. In some embodiments, the shell has a transverse dimension perpendicular to a maximum transverse dimension of at least approximately 5 mm, such as at least approximately 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the shell has a transverse dimension perpendicular to a maximum transverse dimension of less than approximately 20 mm, such as less than approximately 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the shell has a transverse dimension perpendicular to one of the maximum transverse dimensions of approximately 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the transverse dimension perpendicular to the maximum transverse dimension is measured across the surface of the delayed-release oral drug dosage form.

[0139] In some embodiments, the shell is configured to have a thickness for preventing and / or inhibiting exposure of components or portions thereof of the delayed-release oral dosage form to body fluids. In some embodiments, the shell has a thickness of from about 0.4 mm to about 3 mm, such as from about 0.4 mm to about 2 mm, or from about 0.5 mm to about 1.5 mm, measured from the outer surface of the delayed-release oral dosage form to another component thereof. In some embodiments, the shell has a thickness of at least about 0.4 mm, such as at least about 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.2 mm, 2.4 mm, 2.6 mm, 2.8 mm, 3.0 mm. In some embodiments, the shell has a thickness of less than about 3 mm, such as less than about 2.8 mm, 2.6 mm, 2.4 mm, 2.2 mm, 2.0 mm, 1.9 mm, 1.8 mm, 1.7 mm, 1.6 mm, 1.5 mm, 1.4 mm, 1.3 mm, 1.2 mm, 1.1 mm, 1.0 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, or 0.4 mm. In some embodiments, the shell has a thickness of any of about 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.2 mm, 2.4 mm, 2.6 mm, 2.8 mm, 3.0 mm.

[0140] In some embodiments, the shell includes a side surface.

[0141] In some embodiments, the shell includes a barrier material that is impermeable to body fluids such as gastrointestinal fluids. In some embodiments, the shell includes a barrier material that is impermeable to a specific body fluid such as gastric fluid. In some embodiments, the shell includes a barrier material that is impermeable to body fluids at a specific pH, for example, a barrier material that is impermeable to body fluids at a pH less than about 6.

[0142] In some embodiments, the shell comprises an isolating material that is a non-corrosive material. In some embodiments, the shell comprises an isolating material that is non-corrosive in a specific body fluid such as gastric juice. In some embodiments, the shell comprises an isolating material that is non-corrosive in a body fluid at a specific pH, for example, an isolating material that is impermeable to a body fluid at a pH less than about 6. In some embodiments, the isolating material is an enteric material.

[0143] In some embodiments, the shell comprises an isolating material that is a corrosive material having a pH-sensitive corrosion and / or corrosion rate that enables complete release of the JAK inhibitor from the delayed sustained-release oral dosage form prior to exposure of the sustained-release drug component to the body fluid due to corrosion of the shell.

[0144] In some embodiments, the shell comprises an isolating material that is selectively permeable. For example, in some embodiments, the shell is permeable to a body fluid and impermeable to a compound such as a JAK inhibitor.

[0145] In some embodiments, the shell is a thermoreversible material such as a thermoplastic polymer. In some embodiments, the shell comprises a material such as any one or more of an insoluble material, a swellable material, a plasticizer, and another additive, for example, a filler, a binder, a lubricant, a flow promoter, and a disintegrant.

[0146] In some embodiments, the insoluble material is any one or more of cellulose acetate phthalate (CAP), ammonium methacrylate copolymer, poly(lactide-co-glycolide) (PLGA), ethylene-vinyl acetate copolymer, polyethylene (PE), polycaprolactone (PCL), polylactic acid (PLA), cellulose acetate butyrate (CAB), cellulose acetate (CA), polyvinyl acetate (PVAc), polyvinyl acetal diethylamino lactate (AEA), poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1, and ethyl cellulose (EC).

[0147] In some embodiments, the swelling material is one or more of the following: HPC such as high molecular weight hydroxypropyl cellulose (HPC) of about 700 kDa or more; HPMC such as high molecular weight hydroxypropyl methylcellulose or hypromellose (HPMC) of about 500 kDa or more; methylcellulose (MC); PEO such as high molecular weight polyethylene oxide (PEO) of about 700 kDa or more; PVA such as high molecular weight polyvinyl alcohol (PVA) of about 150 kDa or more; polyvinyl acetate (PVAc); polyvinylpyrrolidone (PVP) 80 / 20; methacrylate copolymer; ammoniaalkyl methacrylate copolymer; aminoalkyl methacrylate copolymer E; hydroxypropyl methylcellulose acetate succinate or hypromellose acetate succinate (HPMCAS); hydroxypropyl methylcellulose phthalate (HPMCP); and crospovidone.

[0148] In some embodiments, the plasticizer is one or more of the following: triethyl citrate (TEC), vitamin E polyethylene glycol succinate (TPGS), acetin, triethyl acetyl citrate, tributyl citrate, tributyl o-acetyl citrate, polyoxy-15 hydroxystearate, PEG-40 hydrogenated castor oil, polyoxy-35 castor oil, dibutyl sebacate, diethyl phthalate, glycerin, methyl 4-hydroxybenzoate, castor oil, oleic acid, triacetin, and polyalkylene glycol.

[0149] In some embodiments, the other additives are one or more of acacia, alginate, alginic acid, aluminum acetate, butylparaben, butylated hydroxytoluene, citric acid, calcium carbonate, candelilla wax, croscarmellose sodium, confectionery sugar, colloidal silicone dioxide, cellulose, plain or anhydrous calcium phosphate, carnuba wax, corn starch, carboxymethylcellulose calcium, calcium disodium ethylenediaminetetraacetic acid (EDTA), calcium hydrogen phosphate dehydrated, cetylpyridine chloride, calcium dibasic, tribasic calcium phosphate, dibasic calcium phosphate, disodium hydrogen phosphate, dimethicone, sodium erythrosine, ethylenediaminetetraacetic acid (EDTA), gelatin, glyceryl monooleate, iron oxide, ferrous oxide, iron yellow oxide, iron red oxide, The ingredients are one or more of the following: lactose (hydrate, anhydrous, monohydrate, or spray-dried), microcrystalline cellulose, magnesium carbonate, magnesium oxide, methylparaben, polysorbate 80, propyleneparaben, potassium bicarbonate, potassium sorbate, potato starch, phosphoric acid, polyoxyethylene (40) stearate, sodium starch glycolate, pregelled starch, and sodium crosmellose, sodium lauryl sulfate, starch, silicon dioxide, sodium benzoate, sucrose, sorbic acid, sodium carbonate, sodium saccharin, sodium alginate, silica gel, sorbitan monooleate, sodium chloride, sodium metabisulfite, dehydrated sodium citrate, sodium starch, sodium carboxymethylcellulose, succinic acid, sodium propionate, titanium dioxide, and talc.

[0150] In some embodiments, the shell comprises one or more of ammonia methacrylate copolymer type B, ethylcellulose, stearic acid, and titanium dioxide. In some embodiments, the shell comprises about 60 w / w% to about 70 w / w% of ammonia methacrylate copolymer type B, about 10 w / w% to about 20 w / w% of ethylcellulose, about 15 w / w% to about 25 w / w% of stearic acid, and about 0.1 w / w% to about 0.3 w / w% of titanium dioxide.

[0151] v. Janus kinase (JAK) inhibitors In some embodiments, a JAK inhibitor is a drug that interferes with the JAK-STAT signaling pathway, such as an inhibitor of one or more members associated with the JAK-STAT signaling pathway (e.g., JAKinib). The members associated with the JAK-STAT signaling pathway and their inhibitors are known in the art. See, for example, Rawlings et al., J Cell Sci, 117, 2004, and Schwartz et al., Nat Rev Drug Discov, 17, 2017.

[0152] In some embodiments, the JAK inhibitor is an inhibitor of one or more of Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Janus kinase 3 (JAK3), or tyrosine kinase 2 (TYK2). In some embodiments, the JAK inhibitor is an inhibitor of JAK1 and JAK3. In some embodiments, the JAK inhibitor is an inhibitor of JAK1, JAK3, and JAK2. In some embodiments, the JAK inhibitor is an inhibitor of JAK1, JAK3, JAK2, and TYK2. In some embodiments, the JAK inhibitor is an inhibitor of JAK1 and JAK2. In some embodiments, the JAK inhibitor is an inhibitor of JAK1, JAK2, and TYK2. In some embodiments, the JAK inhibitor is an inhibitor of all JAKs (pan-JAK inhibitor).

[0153] In some embodiments, the JAK inhibitor is selected from the group consisting of tofacitinib, abrocitinib, baricitinib, celduratinib, cucurbitacin I, desernotinib, fedratinib, filgotinib, gandotinib, itacitinib, restaurtinib, momerotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, sorucitinib, upadacitinib, BMS-986165, CHZ868, and SHR0302, or pharmaceutically acceptable salts thereof. In some embodiments, the delayed-release oral drug dosage form comprises a plurality of JAK inhibitors, each JAK inhibitor selected from the group consisting of tofacitinib, abrocitinib, baricitinib, celduratinib, cucurbitacin I, desernotinib, fedratinib, filgotinib, gandotinib, itacitinib, restaurtinib, momerotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, sorucitinib, upadacitinib, BMS-986165, CHZ868, and SHR0302, or pharmaceutically acceptable salts thereof.

[0154] In some embodiments, the JAK inhibitor is tofacitinib or a pharmaceutically acceptable salt thereof. In some embodiments, the JAK inhibitor is a tofacitinib citrate, such as tofacitinib monocitrate. In some embodiments, the JAK inhibitor is a tofacitinib tartrate, such as tofacitinib monotartrate. In some embodiments, the JAK inhibitor is a tofacitinib malate, such as tofacitinib monomalate. In some embodiments, the JAK inhibitor is a tofacitinib oxalate, such as tofacitinib monooxalate.

[0155] In some embodiments, the JAK inhibitor is a pharmaceutically acceptable salt in amorphous form. In some embodiments, the JAK inhibitor is a pharmaceutically acceptable salt in crystalline form.

[0156] In some embodiments, the amount of JAK inhibitor in the delayed-release oral drug formulation is approximately 1 mg to approximately 50 mg, such as approximately 1 mg to approximately 25 mg, approximately 10 mg to approximately 40 mg, approximately 10 mg to approximately 30 mg, approximately 9 mg to approximately 12 mg, approximately 10 mg to approximately 12 mg, approximately 19 mg to approximately 23 mg, or approximately 21 mg to approximately 23 mg. In some embodiments, the amount of JAK inhibitor in the delayed-release oral drug formulation is approximately 1 mg or more, such as approximately 3 mg or more, 4 mg or more, 5 mg or more, 6 mg or more, 7 mg or more, 8 mg or more, 9 mg or more, 10 mg or more, 11 mg or more, 12 mg or more, 13 mg or more, 14 mg or more, 15 mg or more, 16 mg or more, 17 mg or more, 18 mg or more, 19 mg or more, 20 mg or more, 21 mg or more, 22 mg or more, 23 mg or more, 24 mg or more, or 25 mg or more. In some embodiments, the amount of JAK inhibitor in the delayed-release oral drug formulation is approximately 25 mg or less, such as 24 mg or less, 23 mg or less, 22 mg or less, 21 mg or less, 20 mg or less, 19 mg or less, 18 mg or less, 17 mg or less, 16 mg or less, 15 mg or less, 14 mg or less, 13 mg or less, 12 mg or less, 11 mg or less, 10 mg or less, 9 mg or less, 8 mg or less, 7 mg or less, 6 mg or less, 5 mg or less, 4 mg or less, or 3 mg or less. In some embodiments, the amount of JAK inhibitor in the delayed-release oral drug formulation is approximately 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, or 25 mg.

[0157] In some embodiments, the amount of JAK inhibitor in the delayed-release oral drug formulation is approximately 11 mg.

[0158] In some embodiments, the amount of JAK inhibitor in the delayed-release oral drug formulation is approximately 22 mg.

[0159] vi. Composition of sustained-release drug components and delayed-release components The components described herein can be configured in various ways to form the disclosed delayed-release oral drug dosage forms.

[0160] In some embodiments, the delayed-release oral drug dosage form comprises a sustained-release drug component (such as a sustained-release drug layer) and a delay component including a delay member (such as a delay member layer) and a shell, wherein the sustained-release drug component and the delay component are embedded in the shell. In some embodiments, at least a portion of the sustained-release drug component is in direct contact with the shell. In some embodiments, the sustained-release drug component includes a bottom surface, and at least a portion of the bottom surface of the sustained-release drug component is in direct contact with the shell. In some embodiments, the sustained-release drug component includes sides, and at least a portion of the sides is in direct contact with the shell. In some embodiments, the sustained-release drug component includes a bottom surface and sides, and at least a portion of the bottom surface and sides of the sustained-release drug component is in direct contact with the shell. In some embodiments, the sustained-release drug component includes a top surface, and at least a portion of the top surface is not in direct contact with the shell. In some embodiments, at least a portion of the delay member is in direct contact with the shell. In some embodiments, the delay member includes a bottom surface, and at least a portion of the bottom surface of the delay member is in direct contact with the shell. In some embodiments, the delay member includes a bottom surface, and the bottom surface of the delay member is not in direct contact with the shell. In some embodiments, the delay member includes a side surface, and at least a portion of the side surface of the delay member is in direct contact with the shell. In some embodiments, the delay member includes a side surface, and the side surface of the delay member is not in direct contact with the shell. In some embodiments, the delay member includes a bottom surface and a side surface, and at least a portion of the bottom surface and side surface of the delay member is in direct contact with the shell. In some embodiments, the delay member includes a top surface, and at least a portion of the top surface of the delay member is not in direct contact with the shell. In some embodiments, at least a portion of the top surface of the sustained-release drug component is in direct contact with at least a portion of the bottom surface of the delay member. In some embodiments, the surface area of ​​the top surface of the sustained-release drug component is the same as the surface area of ​​the bottom surface of the delay member. In some embodiments, the surface area of ​​the top surface of the sustained-release drug component is smaller than the surface area of ​​the bottom surface of the delay member.

[0161] In some embodiments, the delay member and the shell are configured to prevent the JAK inhibitor from being released from the delayed sustained-release oral dosage form until the delay member is corroded. In some embodiments, less than about 5%, such as less than about 4%, 3%, 2%, or 1% of the JAK inhibitor in the oral dosage form is released from the oral dosage form within about 2 hours after administration of the oral dosage form to a human subject.

[0162] For purposes of illustration, an exemplary configuration of a delayed sustained-release oral dosage form is described below that includes a sustained-release drug component that includes a corrosive material mixed with a JAK inhibitor, a delay member that includes a corrosive material not mixed with the JAK inhibitor, and a shell.

[0163] As shown in FIG. 1A, in some embodiments, the sustained-release drug component, the delay member, and the shell are configured such that the sustained-release drug component is embedded in the shell, the delay member is embedded in the shell, the bottom surface of the sustained-release drug component is in direct contact with the shell, the side surfaces of the sustained-release drug component are in direct contact with the shell, the top surface of the sustained-release drug component is in direct contact with the bottom surface of the delay member, a portion of the bottom surface of the delay member is in direct contact with the shell, and the side surfaces of the delay member are in direct contact with the shell. The portion of the bottom surface of the delay member that is in direct contact with the shell forms a perimeter that extends beyond the top surface of the sustained-release drug component. The shell has an insertion portion for both the sustained-release drug component and the delay member such that the components are embedded in the shell. The top surface of the delayed sustained-release oral dosage form (the surface from which the JAK inhibitor is released from the oral dosage form) is formed from the shell and the delay member. In some embodiments, the shell and the delay member are configured to facilitate the release of the JAK inhibitor from the delayed sustained-release oral dosage form by reducing the attachment of a portion of the oral dosage form to the interior of a human subject's body, which can prevent or inhibit the release of the JAK inhibitor from the oral dosage form to any degree.

[0164] As shown in Figure 1C, in some embodiments, the sustained-release drug component, delay member, and shell are configured such that the sustained-release drug component is embedded in the shell, the delay member is embedded in the shell, the bottom surface of the sustained-release drug component is in direct contact with the shell, the sides of the sustained-release drug component are in direct contact with the shell, the top surface of the sustained-release drug component is in direct contact with the bottom surface of the delay member, and the sides of the delay member are in direct contact with the shell. Optionally, a portion of the bottom surface of the delay member may be in direct contact with the shell. In such embodiments, the portion of the bottom surface of the delay member in direct contact with the shell forms a perimeter extending beyond the top surface of the sustained-release drug component. The shell has insertion portions for both the sustained-release drug component and the delay member so that the components are embedded in the shell. The top surface of the delayed-release oral drug dosage form (the surface from which the JAK inhibitor is released from the oral drug dosage form) is formed from the shell and the delay member. In some embodiments, the shell and delay member are configured to facilitate the release of the JAK inhibitor from the delayed-release oral drug formulation by reducing the adhesion of a portion of the oral drug formulation to the human body, for example, preventing or inhibiting the release of the JAK inhibitor from the oral drug dose to any desired extent.

[0165] As shown in Figure 1D, in some embodiments, the sustained-release drug component, delay member, and shell are configured such that the sustained-release drug component is embedded in the shell, the delay member is embedded in the shell, the bottom surface of the sustained-release drug component is in direct contact with the shell, the sides of the sustained-release drug component are in direct contact with the shell, the top surface of the sustained-release drug component is in direct contact with the bottom surface of the delay member, a portion of the bottom surface of the delay member is in direct contact with the shell, and the sides of the delay member are in direct contact with the shell. The portion of the bottom surface of the delay member in direct contact with the shell forms a perimeter that extends beyond the top surface of the sustained-release drug component. The shell has insertions for both the sustained-release drug component and the delay member so that the components are embedded in the shell. The top surface of the delayed-release oral drug dosage form (the surface from which the JAK inhibitor is released from the oral drug dosage form) is formed from the shell. In some embodiments, the shell is configured to facilitate the release of JAK inhibitors from delayed-release oral drug formulations by reducing the adhesion of a portion of the oral drug formulation to the human body, for example, preventing or inhibiting the release of JAK inhibitors from oral drug doses to any desired extent.

[0166] As shown in Figure 1E, in some embodiments, the sustained-release drug component, delay member, and shell are configured such that the sustained-release drug component is embedded in the shell, the delay member is partially embedded in the shell, the bottom surface of the sustained-release drug component is in direct contact with the shell, the side surface of the sustained-release drug component is in direct contact with the shell, the top surface of the sustained-release drug component is in direct contact with the bottom surface of the delay member, a portion of the bottom surface of the delay member is in direct contact with the shell, a portion of the side surface of the delay member is in direct contact with the shell, and a portion of the side surface of the delay member is not in direct contact with the shell. The portion of the bottom surface of the delay member that is in direct contact with the shell forms a perimeter that extends beyond the top surface of the sustained-release drug component. The shell has insertions for both the sustained-release drug component and the delay member so that the sustained-release drug component is embedded in the shell and the delay member is partially embedded in the shell. The top surface of the delayed-release oral drug dosage form (the surface from which the JAK inhibitor is released from the oral drug dosage form) is formed from the delay member. In some embodiments, the shell and delay member are configured to facilitate the release of the JAK inhibitor from the delayed-release oral drug formulation by reducing the adhesion of a portion of the oral drug formulation to the human body, for example, preventing or inhibiting the release of the JAK inhibitor from the oral drug dose to any desired extent.

[0167] As shown in Figure 1F, in some embodiments, the sustained-release drug component, delay member, and shell are configured such that the sustained-release drug component is embedded in the shell, the bottom surface of the sustained-release drug component is in direct contact with the shell, the sides of the sustained-release drug component are in direct contact with the shell, the top surface of the sustained-release drug component is in direct contact with the bottom surface of the delay member, a portion of the bottom surface of the delay member is in direct contact with the shell, and the sides of the delay member are in direct contact with the shell. The portion of the bottom surface of the delay member that is in direct contact with the shell forms a perimeter that extends beyond the top surface of the sustained-release drug component. The shell has an insertion portion for the sustained-release drug component so that the sustained-release drug component is embedded in the shell. The top surface of the delayed-release oral drug dosage form (the surface from which the JAK inhibitor is released from the oral drug dosage form) is formed from the delay member. In some embodiments, the shell and delay member are configured to facilitate the release of the JAK inhibitor from the delayed-release oral drug formulation by reducing the adhesion of a portion of the oral drug formulation to the human body, for example, preventing or inhibiting the release of the JAK inhibitor from the oral drug dose to any desired extent.

[0168] As shown in Figure 1G, in some embodiments, the sustained-release drug component, delay member, and shell are configured such that the sustained-release drug component is embedded in the shell, the delay member is embedded in the shell, the bottom surface of the sustained-release drug component is in direct contact with the shell, the sides of the sustained-release drug component are in direct contact with the shell, the top surface of the sustained-release drug component is in direct contact with the bottom surface of the delay member, and the sides of the delay member are in direct contact with the shell. The top surface of the sustained-release drug component has the same surface area as the bottom surface of the delay member. The shell has insertions for both the sustained-release drug component and the delay member so that the components are embedded in the shell. The top surface of the delayed-release oral drug dosage form (the surface from which the JAK inhibitor is released from the oral drug dosage form) is formed from the shell. In some embodiments, the shell is configured to facilitate the release of the JAK inhibitor from the delayed-release oral drug dosage form by reducing the adhesion of a portion of the oral drug dosage form to the inside of the human body, for example, which can prevent or inhibit the release of the JAK inhibitor from the oral drug dose to any desired extent.

[0169] As shown in Figure 1H, in some embodiments, the sustained-release drug component, delay member, and shell are configured such that the sustained-release drug component is embedded in the shell, the delay member is embedded in the shell, the bottom surface of the sustained-release drug component is in direct contact with the shell, the sides of the sustained-release drug component are in direct contact with the shell, the top surface of the sustained-release drug component is in direct contact with the bottom surface of the delay member, and the sides of the delay member are in direct contact with the shell. The top surface of the sustained-release drug component has the same surface area as the bottom surface of the delay member. The shell has insertions for both the sustained-release drug component and the delay member so that the components are embedded in the shell. The top surface of the delayed-release oral drug dosage form (the surface from which the JAK inhibitor is released from the oral drug dosage form) is formed from the shell and the delay member. In some embodiments, the shell and delay member are configured to facilitate the release of the JAK inhibitor from the delayed-release oral drug formulation by reducing the adhesion of a portion of the oral drug formulation to the human body, for example, preventing or inhibiting the release of the JAK inhibitor from the oral drug dose to any desired extent.

[0170] The oral drug dosage forms described herein are suitable for oral administration to individual human beings. The drug dosage forms of the present invention may be any size, shape, or weight suitable for oral administration to specific individual human beings, such as children and adults. In some embodiments, the drug dosage form is suitable for oral administration to an individual, and the selection of the size, shape, or weight of the drug dosage form is based on one or more of the individual's attributes, such as height, weight, or age.

[0171] In some embodiments, the surface of the delayed-release oral drug dosage form may have the shape of a capsule, circle, ellipse, bullet, arrowhead, triangle, arc-triangle, square, arc-square, rectangle, arc-rectangle, diamond, pentagon, hexagon, octagon, crescent, almond, or a combination thereof.

[0172] In some embodiments, the delayed-release oral drug dosage form has a maximum cross-sectional dimension of approximately 5 mm to approximately 20 mm, such as approximately 5 mm to approximately 15 mm, approximately 6 mm to approximately 13 mm, or approximately 7 mm to approximately 11 mm. In some embodiments, the delayed-release oral drug dosage form has a maximum cross-sectional dimension of at least approximately 5 mm, such as at least approximately 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the delayed-release oral drug dosage form has a maximum cross-sectional dimension of less than approximately 20 mm, such as less than approximately 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the delayed-release oral drug dosage form has a maximum transverse dimension of approximately 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the maximum transverse dimension is measured across the surface of the delayed-release oral drug dosage form.

[0173] In some embodiments, the delayed-release oral drug dosage form has a transverse dimension perpendicular to a maximum transverse dimension of about 5 mm to about 20 mm, such as about 5 mm to about 15 mm, about 6 mm to about 13 mm, or about 7 mm to about 11 mm. In some embodiments, the delayed-release oral drug dosage form has a transverse dimension perpendicular to a maximum transverse dimension of at least about 5 mm, such as at least about 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the delayed-release oral drug dosage form has a transverse dimension perpendicular to a maximum transverse dimension of less than about 20 mm, such as less than about 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the delayed-release oral drug dosage form has a transverse dimension perpendicular to one of the following maximum transverse dimensions: approximately 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the transverse dimension perpendicular to the maximum transverse dimension is measured across the surface of the delayed-release oral drug dosage form.

[0174] In some embodiments, the delayed-release oral drug dosage form has a thickness of approximately 5 mm to approximately 20 mm, such as approximately 5 mm to approximately 15 mm, approximately 6 mm to approximately 13 mm, or approximately 7 mm to approximately 11 mm. In some embodiments, the delayed-release oral drug dosage form has a thickness of at least approximately 5 mm, such as at least approximately 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the delayed-release oral drug dosage form has a thickness of less than approximately 20 mm, such as less than approximately 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the delayed-release oral drug dosage form has a thickness of approximately 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm.

[0175] In some embodiments, the delayed-release oral drug dosage form has a total weight of approximately 50 mg to approximately 1,000 mg, such as approximately 50 mg to approximately 100 mg, approximately 100 to approximately 200 mg, approximately 200 mg to approximately 300 mg, approximately 300 mg to approximately 400 mg, approximately 400 mg to approximately 500 mg, approximately 500 mg to approximately 600 mg, approximately 600 mg to approximately 700 mg, approximately 700 mg to approximately 800 mg, approximately 800 mg to approximately 900 mg, or approximately 900 mg to approximately 1,000 mg. In some embodiments, the delayed-release oral drug dosage form has a total weight of at least about 50 mg, such as at least about 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1,000 mg. In some embodiments, the delayed-release oral drug dosage form has a total weight of less than approximately 1,000 mg, such as approximately 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 475 mg, 450 mg, 425 mg, 400 mg, 375 mg, 350 mg, 325 mg, 300 mg, 275 mg, 250 mg, 225 mg, 200 mg, 175 mg, 150 mg, 125 mg, 100 mg, 75 mg, or less than 50 mg. In some embodiments, the delayed-release oral drug dosage form has a total weight of approximately 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1,000 mg.

[0176] In some embodiments, the surface of a delayed-release oral drug dosage form configured to release at least a portion of the JAK inhibitor is configured to reduce adhesion of the oral drug dosage form or a portion thereof to the inside of a human body. In some embodiments, the surface or at least a portion thereof configured to release at least a portion of the JAK inhibitor is not flat and, for example, exceeds a surface tolerance threshold. In some embodiments, the surface or at least a portion thereof configured to release at least a portion of the JAK inhibitor is flat and, for example, within a surface tolerance threshold.

[0177] In some embodiments, the delayed-release oral drug dosage form is not an osmotic dosage form, such as an osmotically controlled-release oral drug dosage form.

[0178] In some embodiments, the delayed-release oral drug dosage form comprises two or more dosage units, each dosage unit comprising at least partially a sustained-release drug component and a delay component. For example, in some embodiments, the delayed-release oral drug form comprises a shell containing a first sustained-release drug component and a second sustained-release drug component embedded therein, as well as a first delay member and a second delay member, the first delay member preventing the release of the JAK inhibitor from the first sustained-release drug component for about 2 to 6 hours after administration of the delayed-release drug dosage form to a human subject, and the second delay member preventing the release of the JAK inhibitor from the first sustained-release drug component for about 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human subject. In some embodiments, the two dosage units are the same. In some embodiments, the two dosage units are different. In some embodiments, the two dosage units are stacked back-to-back. In some embodiments, the two dosage units are separated by a shell.

[0179] vii. Additional ingredients In some embodiments, the delayed-release dosage form includes additional components, such as an outer coating. In some embodiments, the outer coating is a flavor coating. In some embodiments, the outer coating is a sugar coating. In some embodiments, the outer coating is a cosmetic coating. In some embodiments, the outer coating is a color coating. In some embodiments, the outer coating is a film coating. In some embodiments, the outer coating is a polymer coating. In some embodiments, the additional components are a label such as a company name, abbreviation, or logo; a drug label or drug name such as a drug brand name and / or drug chemical name or abbreviation; drug quantity or strength; an identification barcode; or any combination thereof.

[0180] B. Release Profile of Delayed-Release Oral Drug Dosage Forms The delayed-release oral drug formulations described herein are formulated and configured to delay the release of a JAK inhibitor from the oral drug formulation for a desired period of time after administration to a human subject, and then release the JAK inhibitor from the oral drug formulation according to a desired release profile. In some embodiments, the delayed-release oral drug formulation includes an immediate-release component, such as an immediate-release component containing a JAK inhibitor. In some embodiments, the immediate-release component releases the JAK inhibitor after an initial delay (i.e., the oral drug formulation is configured such that the immediate-release component delays the release of the drug contained therein from the oral drug formulation for a desired period of time).

[0181] In some embodiments, the JAK inhibitor is prevented and / or inhibited from being released from the delayed-release oral drug formulation for approximately 1 to 7 hours after administration to a human subject, such as approximately 1 to 6 hours, approximately 2 to 6 hours, approximately 2 to 4 hours, approximately 2 to 3 hours, or approximately 1.5 to 3 hours. In some embodiments, the JAK inhibitor is prevented and / or inhibited from being released from the delayed-release oral drug formulation for at least approximately 1 hour but not exceeding approximately 7 hours after administration to a human subject, such as at least approximately 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, 6 hours, or 6.5 hours. In some embodiments, the JAK inhibitor is prevented and / or inhibited from being released from the delayed-release oral drug formulation for a period of approximately 7 hours or less after administration to a human subject, such as approximately 6.5 hours, 6 hours, 5.5 hours, 5 hours, 4.5 hours, 4 hours, 3.5 hours, 3 hours, 2.5 hours, 2 hours, 1.5 hours, or 1 hour. In some embodiments, the JAK inhibitor is prevented and / or inhibited from being released from the delayed-release oral drug formulation for at least approximately 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, 6 hours, 6.5 hours, or 7 hours after administration to a human subject.

[0182] Following a delay in the release of the JAK inhibitor, the oral drug formulations described herein are configured to subsequently release the JAK inhibitor according to a desired release profile. As is known in the art, the efficacy of tofacitinib is observed at plasma concentrations of about 17 ng / mL or higher. See, for example, Meyer et al., J Inflammation, 7, 2010. In some embodiments, when a delayed-release oral drug formulation is administered to a human organism, the mean area under the plasma concentration-time curve after complete decomposition of the delaying component, such as the delaying agent, or a portion thereof, is about 17 ng-hr / mL per 1 mg of JAK inhibitor administered to about 42 ng-hr / mL per 1 mg of JAK inhibitor administered to. In some embodiments, when a delayed-release oral drug formulation is administered to a human organism, the mean area under the plasma concentration-time curve after complete decomposition of the delaying component, such as the delaying agent, or a portion thereof, is greater than about 17 ng-hr / mL per 1 mg of JAK inhibitor administered over a 24-hour period of about 6 hours to about 15 hours. In some embodiments, when a delayed-release oral drug formulation is administered to a human individual, the mean area under the plasma concentration-time curve after complete decomposition of the delaying component, such as the delaying member, or a portion thereof, is less than approximately 17 ng-hr / mL per 1 mg of the administered JAK inhibitor over a 24-hour period of approximately 9 to approximately 18 hours. In some embodiments, the delayed-release oral drug formulation includes sufficient drug-free intervals to avoid a decrease in efficacy.

[0183] In some embodiments, the delayed-release oral drug dosage form is configured to release the JAK inhibitor in the following manner: (i) about 20-40% or less of the total JAK inhibitor is released 1 hour after complete corrosion of the delaying component, such as a delaying member, or a portion thereof; (ii) about 25-45% or more and 65-85% or less of the total JAK inhibitor is released 2.5 hours after complete corrosion of the delaying component, such as a delaying member, or a portion thereof; and (iii) about 65-85% or more of the total JAK inhibitor is released 5 hours after complete corrosion of the delaying component, such as a delaying member, or a portion thereof. In some embodiments, the delayed-release oral drug dosage form is configured to release the JAK inhibitor in the following manner: (i) about 30% or less of the total JAK inhibitor is released 1 hour after complete corrosion of the delaying component, such as a delaying member, or a portion thereof; (ii) about 35% or more and 75% or less of the total JAK inhibitor is released 2.5 hours after complete corrosion of the delaying component, such as a delaying member, or a portion thereof; and (iii) about 70% or more of the total JAK inhibitor is released 5 hours after complete corrosion of the delaying component, such as a delaying member, or a portion thereof.

[0184] In some embodiments, the release of a JAK inhibitor from a delayed-release oral drug formulation includes a zero-order release profile, a primary-order release profile, a delayed-release profile, a pulsed-release profile, a repeated-pulsed-release profile, or a combination thereof.

[0185] In some embodiments, the release of the JAK inhibitor from the delayed-release oral drug dosage form is based on an in vivo release rate. In some embodiments, the release of the JAK inhibitor from the delayed-release oral drug dosage form is based on an in vitro release rate. In some embodiments, the release of the JAK inhibitor is based on an in vitro elution technique that includes the use of a USP rotary paddle device rotated at approximately 50 rpm and a test medium containing 900 mL of 0.05 M potassium phosphate buffer at pH 6.8 and 37°C. In some embodiments, the delayed component has an in vitro elution rate of approximately 2% to approximately 40% per hour, based on an in vitro elution technique that includes the use of a USP rotary paddle device rotated at approximately 50 rpm and a test medium containing 900 mL of 0.05 M potassium phosphate buffer at pH 6.8 and 37°C.

[0186] In some embodiments, T max This occurs within approximately 6 hours, such as within 5.5 hours, 5 hours, 4.5 hours, or 4 hours, after the complete corrosion of the delaying component, such as the delaying member, or a portion thereof.

[0187] In some embodiments, when administered to a human individual, geometric mean plasma C max vs C min The ratio is approximately 10 to 100, such as either 20 to 40 or 20 to 30.

[0188] In some embodiments, when a delayed-release oral drug formulation is administered to a human organism, the release of the JAK inhibitor following the complete corrosion of the delaying component, such as a delaying agent, or a portion thereof, is bioequivalent to XELJANZ IR (immediate-release) administered twice daily to a human organism. In some embodiments, when a delayed-release oral drug formulation is administered to a human organism, the release of the JAK inhibitor following the complete corrosion of the delaying component, such as a delaying agent, or a portion thereof, is bioequivalent to XELJANZ XR (sustained-release) administered once daily to a human organism. In some embodiments, the range of values ​​for the pharmacokinetic parameters of the JAK inhibitor in the delayed-release oral drug formulation described herein is approximately 60% to approximately 145%, such as approximately 65% ​​to approximately 140%, approximately 70% to approximately 135%, approximately 75% to approximately 130%, approximately 80% to approximately 125%, approximately 85% to approximately 120%, or approximately 90% to approximately 115% of the pharmacokinetic parameters of the reference PK curve of the reference oral drug formulation of the JAK inhibitor. In some embodiments, each of the pharmacokinetic parameters of a desired composite PK profile may have the same or different acceptable thresholds. For example, in some embodiments, the desired composite profile includes two or more pharmacokinetic parameters, where one pharmacokinetic parameter has a higher acceptable threshold than another pharmacokinetic parameter.

[0189] D. Exemplary delayed-release oral drug formulations In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor is provided, the delayed-release oral drug dosage form comprising a delayed component comprising a delayed-release drug component layer containing a first corrosive material mixed with a JAK inhibitor, a delayed component layer containing a second corrosive material not mixed with a JAK inhibitor, and a shell, wherein the delayed component layer surrounds the delayed-release drug component layer, and the delayed component layer prevents the release of the JAK inhibitor from the delayed-release oral drug dosage form for about 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human organism. The sustained-release drug component layer, the delay member layer, and the shell are configured such that the sustained-release drug component layer is embedded in the shell, the delay member layer is embedded in the shell, the bottom surface of the sustained-release drug component layer is in direct contact with the shell, the sides of the sustained-release drug component layer are in direct contact with the shell, the top surface of the sustained-release drug component layer is in direct contact with the bottom surface of the delay member layer, a portion of the bottom surface of the delay member layer is in direct contact with the shell, and the sides of the delay member layer are in direct contact with the shell. The portion of the bottom surface of the delay member layer that is in direct contact with the shell forms a perimeter that extends beyond the top surface of the sustained-release drug component layer. The shell has insertion portions for both the sustained-release drug component layer and the delay member layer so that the components are embedded in the shell. The top surface of the delayed-release oral drug dosage form (the surface from which the JAK inhibitor is released from the oral drug dosage form) is formed from the shell and the delay member layer. The top surface of the delay member layer and the top surface of the sustained-release drug component form a capsule shape.

[0190] In some embodiments, an oral drug dosage form representing a portion of the delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor described herein is provided, comprising a sustained-release drug component layer containing a first corrosive material mixed with a JAK inhibitor, and a shell, wherein the sustained-release drug component has a length of about 9 mm to about 9.8 mm, such as about 9.4 mm, a width of about 4.8 mm to about 5.6 mm, such as about 5.2 mm, and a height (thickness) of about 0.7 mm to about 1.5 mm, such as about 1.1 mm, and the shell has a length of about 1.4 mm to about 12.2 mm, such as about 11.8 mm, a width of about 7.2 mm to about 8.0 mm, such as about 7.6 mm, and a height (thickness) of about 1.9 mm to about 3.0 mm, such as about 2.3 mm or about 2.6 mm. In some embodiments, the oral drug dosage form representing a portion of the delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor described herein does not include a delaying member.

[0191] In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor comprises a delayed-release drug component layer containing a first corrosive material mixed with the JAK inhibitor, a delayed component layer containing a second corrosive material not mixed with the JAK inhibitor, and a shell, wherein the delayed component layer surrounds the delayed-release drug component layer, and the delayed component layer prevents the release of the JAK inhibitor from the delayed-release oral drug dosage form for about 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human organism, and the delayed-release drug component has a length of about 9 mm to 9.8 mm, such as about 9.4 mm, and a diameter of about 5.2 mm. The structure has a width of approximately 4.8 mm to approximately 5.6 mm and a height (thickness) of approximately 0.7 mm to approximately 1.5 mm, such as approximately 1.1 mm. The delay member has a length of approximately 9.8 mm to approximately 10.6 mm, such as approximately 10.2 mm, a width of approximately 5.6 mm to approximately 6.4 mm, such as approximately 6.0 mm, and a height (thickness) of approximately 0.1 mm to approximately 1.1 mm, such as approximately 0.4 mm or approximately 0.7 mm. The shell has a length of approximately 11.4 mm to approximately 12.2 mm, such as approximately 11.8 mm, a width of approximately 7.2 mm to approximately 8.0 mm, such as approximately 7.6 mm, and a height (thickness) of approximately 1.9 mm to approximately 3.0 mm, such as approximately 2.3 mm or approximately 2.6 mm. In some embodiments, the delayed-release oral drug dosage form is as shown in Figures 2A to 2B.

[0192] In some embodiments, the sustained-release drug component comprises about 25% to about 45% by weight (e.g., about 35% by weight) of tofacitinib citrate relative to the weight of the sustained-release drug component, about 30% to about 50% by weight (e.g., about 40% by weight) of hydroxypropylcellulose relative to the weight of the sustained-release drug component, about 5% to about 15% by weight (e.g., about 10% by weight) of vinylpyrrolidone-vinyl acetate copolymer relative to the weight of the sustained-release drug component, and about 5% to about 25% by weight (e.g., about 15% by weight) of glycerin relative to the weight of the sustained-release drug component. In some embodiments, the delay member comprises hydroxypropyl cellulose in an amount of about 75% to about 95% by weight (e.g., about 85% by weight) relative to the weight of the delay member, triethyl citrate in an amount of about 5% to about 25% by weight (e.g., about 15% by weight) relative to the weight of the delay member, and titanium dioxide in an amount of about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) relative to the weight of the delay member.

[0193] In some embodiments, the shell contains ammonia methacrylate copolymer type B in an amount of about 55% to about 75% by weight (e.g., about 65% by weight) relative to the shell, ethyl cellulose in an amount of about 5% to about 25% by weight (e.g., about 15% by weight) relative to the weight of the shell, stearic acid in an amount of about 10% to about 30% by weight (e.g., about 20% by weight) relative to the weight of the shell, and titanium dioxide in an amount of about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) relative to the weight of the shell.

[0194] In some embodiments, the sustained-release drug component comprises about 25% to about 45% by weight (e.g., about 25% by weight) of tofacitinib citrate relative to the weight of the sustained-release drug component, about 30% to about 50% by weight (e.g., about 40% by weight) of hydroxypropyl cellulose relative to the weight of the sustained-release drug component, about 5% to about 15% by weight (e.g., about 20% by weight) of vinylpyrrolidone-vinyl acetate copolymer relative to the weight of the sustained-release drug component, and about 5% to about 25% by weight (e.g., about 15% by weight) of triethyl citrate (TEC) relative to the weight of the sustained-release drug component.

[0195] In some embodiments, the retarder comprises hydroxypropyl cellulose in an amount of about 75% to about 95% by weight (e.g., about 90% by weight) relative to the weight of the retarder, triethyl citrate in an amount of about 5% to about 25% by weight (e.g., about 9.8% by weight) relative to the weight of the retarder, and titanium dioxide in an amount of about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) relative to the weight of the retarder.

[0196] In some embodiments, the shell contains ethylcellulose, USP / NF, etc., in an amount of about 75% to about 85% by weight (e.g., about 80% by weight) relative to the shell, dibutyl sebacate (DBS), etc., in an amount of about 5% to about 25% by weight (e.g., about 19.8% by weight) relative to the weight of the shell, and titanium dioxide, etc., in an amount of about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) relative to the weight of the shell.

[0197] In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor comprises a delayed-release drug component layer containing a first corrosive material mixed with the JAK inhibitor, a delayed component layer containing a second corrosive material not mixed with the JAK inhibitor, and a shell, wherein the delayed component layer surrounds the delayed-release drug component layer, and the delayed component layer releases the JAK inhibitor from the delayed-release oral drug dosage form for approximately 2 to 6 hours after administration to a human individual. To prevent leakage, the sustained-release drug component has a diameter of approximately 7.0 mm to 10.0 mm (e.g., approximately 7.4 mm) and a height (thickness) of approximately 0.2 mm to 1.6 mm (e.g., approximately 1.4 mm). The delay member has a diameter of approximately 7.0 mm to 11.0 mm (e.g., approximately 8.2 mm) and a height (thickness) of approximately 0.2 mm to 1.2 mm (e.g., approximately 0.4 mm). The shell has a diameter of approximately 9.0 mm to 11.0 mm (e.g., approximately 9.8 mm) and a height (thickness) of approximately 1.0 mm to 3.0 mm (e.g., approximately 2.2 mm).

[0198] In some embodiments, the sustained-release drug component comprises about 25% to about 45% by weight (e.g., about 35% by weight) of tofacitinib citrate relative to the weight of the sustained-release drug component, about 30% to about 50% by weight (e.g., about 40% by weight) of hydroxypropylcellulose relative to the weight of the sustained-release drug component, about 10% to about 20% by weight (e.g., about 15% by weight) of glycerol relative to the weight of the sustained-release drug component, and about 5% to about 15% by weight (e.g., about 10% by weight) of vinylpyrrolidone-vinyl acetate copolymer relative to the weight of the sustained-release drug component.

[0199] In some embodiments, the delay member comprises about 75% to about 95% by weight (e.g., about 85% by weight) of hydroxypropyl cellulose and about 5% to about 25% by weight (e.g., about 15% by weight) of triethyl citrate relative to the weight of the delay member.

[0200] In some embodiments, the shell contains about 50% to about 80% by weight (e.g., about 65% by weight) of ammonium methacrylate copolymer relative to the shell, about 10% to about 20% by weight (e.g., about 15% by weight) of ethylcellulose (EC-N10) relative to the weight of the shell, about 10% to about 30% by weight (e.g., about 20% by weight) of stearic acid (SA, 95% by weight; SA95% by weight) relative to the weight of the shell, and about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) of titanium dioxide relative to the weight of the shell.

[0201] In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor comprises a delayed-release drug component layer containing a first corrosive material mixed with the JAK inhibitor, a delayed component layer containing a second corrosive material not mixed with the JAK inhibitor, and a shell, wherein the delayed component layer surrounds the delayed-release drug component layer, and the delayed component layer prevents the release of the JAK inhibitor from the delayed-release oral drug dosage form for about 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human individual, and the delayed-release drug component is about 4.0 mm, or about 3.0 mm to about 5.0 mm. The components have a length of approximately 4.6 mm, a width of approximately 4.0 mm to 5.6 mm, and a height (thickness) of approximately 0.8 mm to 2.0 mm, such as approximately 1.35 mm. The delay members have a length of approximately 3.0 mm to 5.0 mm, a width of approximately 5.0 mm to 6.4 mm, such as approximately 5.4 mm, and a height (thickness) of approximately 0.2 mm to 1.2 mm, such as approximately 0.5 mm. The shells have a length of approximately 3.0 mm to 5.0 mm, such as approximately 4.0 mm, a width of approximately 6.4 mm to 8.0 mm, such as approximately 7.0 mm, and a height (thickness) of approximately 1.5 mm to 3.5 mm, such as approximately 2.55 mm.

[0202] In some embodiments, the sustained-release drug component comprises about 25% to about 45% by weight (e.g., about 35% by weight) of tofacitinib citrate relative to the weight of the sustained-release drug component, about 30% to about 50% by weight (e.g., about 40% by weight) of hydroxypropylcellulose relative to the weight of the sustained-release drug component, about 10% to about 20% by weight (e.g., about 15% by weight) of glycerol relative to the weight of the sustained-release drug component, and about 5% to about 15% by weight (e.g., about 10% by weight) of vinylpyrrolidone-vinyl acetate copolymer relative to the weight of the sustained-release drug component.

[0203] In some embodiments, the delay member comprises about 75% to about 95% by weight (e.g., about 85% by weight) of hydroxypropyl cellulose and about 5% to about 25% by weight (e.g., about 15% by weight) of triethyl citrate relative to the weight of the delay member.

[0204] In some embodiments, the shell contains about 50% to about 80% by weight (e.g., about 65% by weight) of ammonium methacrylate copolymer relative to the shell, about 10% to about 20% by weight (e.g., about 15% by weight) of ethylcellulose (EC-N10) relative to the weight of the shell, about 10% to about 30% by weight (e.g., about 20% by weight) of stearic acid (SA, 95% by weight; SA95% by weight) relative to the weight of the shell, and about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) of titanium dioxide relative to the weight of the shell.

[0205] In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor comprises a delayed-release drug component layer containing a first corrosive material mixed with the JAK inhibitor, a delayed component layer containing a second corrosive material not mixed with the JAK inhibitor, and a shell, wherein the delayed component layer surrounds the delayed-release drug component layer, and the delayed component layer prevents the release of the JAK inhibitor from the delayed-release oral drug dosage form for approximately 2 to 6 hours after administration to a human individual. The drug component has a diameter of approximately 5.0 mm to 9.0 mm, such as approximately 8.6 mm, and a height (thickness) of approximately 0.2 mm to 1.6 mm, such as approximately 0.6 mm; the delay member has a diameter of approximately 7.0 mm to 11.0 mm, such as approximately 10.4 mm, and a height (thickness) of approximately 0.2 mm to 1.2 mm, such as approximately 0.8 mm or approximately 1.2 mm; and the shell has a diameter of approximately 9.0 mm to 13.0 mm, such as approximately 11.6 mm, and a height (thickness) of approximately 1.0 mm to 3.0 mm, such as approximately 2.2 mm or approximately 2.6 mm.

[0206] In some embodiments, the sustained-release drug component comprises about 30% to about 50% by weight (e.g., about 40% by weight) of tofacitinib citrate relative to the weight of the sustained-release drug component, about 20% to about 40% by weight (e.g., about 30% by weight) of hydroxypropylcellulose relative to the weight of the sustained-release drug component, about 10% to about 30% by weight (e.g., about 20% by weight) of PEG400 relative to the weight of the sustained-release drug component, and about 5% to about 15% by weight (e.g., about 10% by weight) of vinylpyrrolidone-vinyl acetate copolymer relative to the weight of the sustained-release drug component.

[0207] In some embodiments, the delay member comprises about 75% to about 95% by weight (e.g., about 85% by weight) of hydroxypropyl cellulose and about 5% to about 25% by weight (e.g., about 15% by weight) of PEG400 relative to the weight of the delay member.

[0208] In some embodiments, the shell contains about 50% to about 80% by weight (e.g., about 65% by weight) of ammonium methacrylate copolymer relative to the shell, about 10% to about 20% by weight (e.g., about 15% by weight) of ethylcellulose (EC-N10) relative to the weight of the shell, about 10% to about 30% by weight (e.g., about 20% by weight) of stearic acid (SA, 95% by weight; SA95% by weight) relative to the weight of the shell, and about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) of titanium dioxide relative to the weight of the shell.

[0209] In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor comprises a delayed-release drug component layer containing a first corrosive material mixed with the JAK inhibitor, a delayed-release component layer containing a second corrosive material not mixed with the JAK inhibitor, and a shell, wherein the delayed-release component layer surrounds the delayed-release drug component layer, and the delayed-release component layer releases the delayed-release oral drug for approximately 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human individual. To prevent the release of the JAK inhibitor from the dosage form, the sustained-release drug component has a diameter of approximately 5.0 mm to 9.0 mm, such as approximately 6.0 mm, approximately 6.8 mm, or approximately 7.4 mm, and a height (thickness) of approximately 0.4 mm to 1.6 mm, such as approximately 0.8 mm or approximately 1.4 mm, while the delaying member has a diameter of approximately 7.0 mm to 11.0 mm, such as approximately 8.4 mm or approximately 9.4 mm, and a height (thickness) of approximately 0.2 mm to 1.2 mm, such as approximately 0.4 mm or approximately 1.0 mm.

[0210] In some embodiments, the sustained-release drug component comprises about 25% to about 50% by weight (e.g., about 30% or about 40% by weight) of tofacitinib citrate relative to the weight of the sustained-release drug component, about 20% to about 60% by weight (e.g., about 30% or about 55% by weight) of hydroxypropylcellulose relative to the weight of the sustained-release drug component, about 10% to about 25% by weight (e.g., about 15% or about 20% by weight) of glycerol relative to the weight of the sustained-release drug component, and about 0% to about 30% by weight (e.g., about 10% or about 0% by weight) of vinylpyrrolidone-vinyl acetate copolymer relative to the weight of the sustained-release drug component.

[0211] In some embodiments, the delay member comprises about 75% to about 95% by weight (e.g., about 85% by weight) of hydroxypropyl cellulose and about 5% to about 25% by weight (e.g., about 15% by weight) of triethyl citrate relative to the weight of the delay member.

[0212] In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor comprises a delayed-release drug component layer containing a first corrosive material mixed with the JAK inhibitor, a delayed component layer containing a second corrosive material not mixed with the JAK inhibitor, and a shell, wherein the delayed component layer surrounds the delayed-release drug component layer, and the delayed component layer prevents the release of the JAK inhibitor from the delayed-release oral drug dosage form for about 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human individual, and the delayed-release drug component has a length of about 5.0 mm to about 11.0 mm, such as about 5.4 mm, about 8.4 mm, or about 11.0 mm, and a width of about 4.0 mm to about 5.6 mm, such as about 5.2 mm. The delay member has a length of approximately 5.0 mm to 11.0 mm, such as approximately 5.4 mm, approximately 8.4 mm, or approximately 11.0 mm, a width of approximately 5.0 mm to 6.4 mm, such as approximately 6.0 mm, and a height (thickness) of approximately 0.2 mm to 1.2 mm, such as approximately 0.6 mm or approximately 0.7 mm. The shell has a length of approximately 5.0 mm to 11.0 mm, such as approximately 5.4 mm, approximately 8.4 mm, or approximately 11.0 mm, a width of approximately 6.4 mm to 8.0 mm, such as approximately 7.6 mm, and a height (thickness) of approximately 2.2 mm to 3.4 mm, such as approximately 2.4 mm, approximately 2.7 mm, or approximately 2.8 mm.

[0213] In some embodiments, the sustained-release drug component comprises about 15% to about 35% by weight (e.g., about 25% by weight) of tofacitinib citrate relative to the weight of the sustained-release drug component, about 30% to about 50% by weight (e.g., about 40% by weight) of hydroxypropylcellulose relative to the weight of the sustained-release drug component, about 10% to about 20% by weight (e.g., about 15% by weight) of triethyl citrate relative to the weight of the sustained-release drug component, and about 10% to about 30% by weight (e.g., about 20% by weight) of vinylpyrrolidone-vinyl acetate copolymer relative to the weight of the sustained-release drug component.

[0214] In some embodiments, the delay member comprises hydroxypropyl cellulose in an amount of about 75% to about 95% by weight (e.g., about 90% by weight) relative to the weight of the delay member, triethyl citrate in an amount of about 5% to about 25% by weight (e.g., about 10% by weight) relative to the weight of the delay member, and titanium dioxide in an amount of about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) relative to the weight of the delay member.

[0215] In some embodiments, the shell comprises ethylcellulose (EC-N10) in an amount of about 70% to about 90% by weight (e.g., about 80% by weight) relative to the weight of the shell, dibutyl sebacate in an amount of about 10% to about 30% by weight (e.g., about 20% by weight) relative to the weight of the shell, and titanium dioxide in an amount of about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) relative to the weight of the shell.

[0216] In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor comprises two sustained-release drug component layers, each containing a first corrosive material mixed with the JAK inhibitor; two delay component layers, each containing a second corrosive material not mixed with the JAK inhibitor; and two delay component layers, each containing a shell. The delay component layers surround the sustained-release drug component layers, and the delay component layers prevent the release of the JAK inhibitor from the delayed-release oral drug dosage form for approximately 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human subject. The components have a length of approximately 2.0 mm to 2.8 mm (e.g., approximately 2.4 mm), a width of approximately 4.0 mm to 5.6 mm (e.g., approximately 4.8 mm), and a height (thickness) of approximately 0.2 mm to 1.2 mm (e.g., approximately 0.8 mm). The delay members have a width of approximately 2.0 mm to 2.8 mm (e.g., approximately 2.4 mm), a width of approximately 5.0 mm to 6.4 mm (e.g., approximately 5.6 mm), and a height (thickness) of approximately 0.1 mm to 1.1 mm (e.g., approximately 0.4 mm). The shell has a length of approximately 2.0 mm to 2.8 mm (e.g., approximately 2.4 mm), a width of approximately 6.4 mm to 8.0 mm (e.g., approximately 7.2 mm), and a height (thickness) of approximately 2.2 mm to 3.4 mm (e.g., approximately 2.8 mm).

[0217] In some embodiments, the sustained-release drug component comprises about 15% to about 35% by weight (e.g., about 25% by weight) of tofacitinib citrate relative to the weight of the sustained-release drug component, about 30% to about 50% by weight (e.g., about 40% by weight) of hydroxypropylcellulose relative to the weight of the sustained-release drug component, about 10% to about 20% by weight (e.g., about 15% by weight) of triethyl citrate relative to the weight of the sustained-release drug component, and about 10% to about 30% by weight (e.g., about 20% by weight) of vinylpyrrolidone-vinyl acetate copolymer relative to the weight of the sustained-release drug component.

[0218] In some embodiments, the delay member comprises about 75% to about 95% by weight (e.g., about 90% by weight) of hydroxypropyl cellulose and about 5% to about 25% by weight (e.g., about 10% by weight) of triethyl citrate relative to the weight of the delay member.

[0219] In some embodiments, the shell contains about 50% to about 80% by weight (e.g., about 65% by weight) of ammonium methacrylate copolymer relative to the shell, about 10% to about 20% by weight (e.g., about 15% by weight) of ethylcellulose (EC-N10) relative to the weight of the shell, about 10% to about 30% by weight (e.g., about 20% by weight) of stearic acid (SA, 95% by weight; SA95% by weight) relative to the weight of the shell, and about 0.5% to about 0.05% by weight (e.g., about 0.2% by weight) of titanium dioxide relative to the weight of the shell.

[0220] In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor is provided, the delayed-release oral drug dosage form comprising a delayed component comprising a delayed-release drug component layer containing a first corrosive material mixed with a JAK inhibitor, a delayed component layer containing a second corrosive material not mixed with a JAK inhibitor, and a shell, wherein the delayed component layer surrounds the delayed-release drug component layer, and the delayed component layer prevents the release of the JAK inhibitor from the delayed-release oral drug dosage form for about 2 to 6 hours after administration of the delayed-release oral drug dosage form to a human organism. The sustained-release drug component layer, the delay member layer, and the shell are configured such that the sustained-release drug component layer is embedded in the shell, the delay member layer is embedded in the shell, the bottom surface of the sustained-release drug component layer is in direct contact with the shell, the sides of the sustained-release drug component layer are in direct contact with the shell, the top surface of the sustained-release drug component layer is in direct contact with the bottom surface of the delay member layer, a portion of the bottom surface of the delay member layer is in direct contact with the shell, and the sides of the delay member layer are in direct contact with the shell. The portion of the bottom surface of the delay member layer that is in direct contact with the shell forms a perimeter that extends beyond the top surface of the sustained-release drug component layer. The shell has insertion portions for both the sustained-release drug component layer and the delay member layer so that the component is embedded in the shell. The top surface of the delayed-release oral drug dosage form (the surface from which the JAK inhibitor is released from the oral drug dosage form) is formed from the shell and the delay member layer. The top surface of the delay member layer and the top surface of the sustained-release drug component are circular in shape. For example, see Figures 2C-2D for a cylinder-shaped delayed-release oral drug dosage form.

[0221] In some embodiments, a delayed-release oral drug dosage form of a Janus kinase (JAK) inhibitor comprises a delayed-release drug component layer containing a first corrosive material mixed with the JAK inhibitor, a delayed component layer containing a second corrosive material not mixed with the JAK inhibitor, and a shell, wherein the delayed component layer surrounds the delayed-release drug component layer, and the delayed component layer prevents the release of the JAK inhibitor from the delayed-release oral drug dosage form for approximately 2 to 6 hours after administration to a human individual. The delayed-release drug component has a diameter of approximately 8.2 mm to 9.0 mm, such as approximately 8.6 mm, and a height (thickness) of approximately 0.2 mm to 1.0 mm, such as approximately 0.6 mm; the delay member has a diameter of approximately 10.0 mm to 10.8 mm, such as approximately 10.4 mm, and a height (thickness) of approximately 0.8 mm to 1.6 mm, such as approximately 1.2 mm; and the shell has a diameter of approximately 11.2 mm to 12.0 mm, such as approximately 11.6 mm, and a height (thickness) of approximately 2.2 mm to 3.0 mm, such as approximately 2.6 mm. In some embodiments, the delayed-release oral drug dosage form is in the form shown in Figures 2C to 2D.

[0222] In some embodiments, the sustained-release drug component comprises about 30% to about 50% by weight (e.g., about 40% by weight) of tofacitinib citrate relative to the weight of the sustained-release drug component, about 20% to about 40% by weight (e.g., about 30% by weight) of hydroxypropyl cellulose relative to the weight of the sustained-release drug component, about 5% to about 15% by weight (e.g., about 10% by weight) of vinylpyrrolidone-vinyl acetate copolymer relative to the weight of the sustained-release drug component, and about 10% to about 30% by weight (e.g., about 20% by weight) of polyethylene glycol 400 relative to the weight of the sustained-release drug component.

[0223] In some embodiments, the delay member comprises about 75% to about 95% by weight (e.g., about 85% by weight) of hydroxypropyl cellulose and about 5% to about 25% by weight (e.g., about 15% by weight) of polyethylene glycol 400 relative to the weight of the delay member.

[0224] In some embodiments, the shell comprises ammonia methacrylate copolymer type B in an amount of about 50% to about 80% by weight (e.g., about 60% by weight) relative to the shell, ethylcellulose in an amount of about 10% to about 30% by weight (e.g., about 20% by weight) relative to the weight of the shell, and stearic acid in an amount of about 10% to about 30% by weight (e.g., about 20% by weight) relative to the weight of the shell.

[0225] In some embodiments, provided herein are sustained-release oral drug dosage forms comprising a delay component containing a sustained-release drug component comprising a plurality of sustained-release beads comprising a JAK inhibitor. In some embodiments, the delay component comprises at least a portion thereof, such as a delay member, configured to release the JAK inhibitor from the sustained-release oral drug dosage form at a desired time after administration. In some embodiments, the sustained-release beads comprise a homogeneous mixture comprising tofacitinib or a pharmaceutically acceptable salt thereof, and one or more agents for controlling the release of tofacitinib therefrom.

[0226] In some embodiments, provided herein are delayed-release oral drug dosage forms comprising a delay component containing a sustained-release drug component comprising a plurality of sustained-release beads comprising a JAK inhibitor, wherein the sustained-release beads are coated with an agent for controlling the release of the JAK inhibitor therefrom. In some embodiments, the delay component comprises at least a portion thereof, such as a delay member, configured to release the JAK inhibitor from the delayed-release oral drug dosage form at a desired time after administration. In some embodiments, the sustained-release beads comprise a homogeneous mixture comprising tofacitinib or a pharmaceutically acceptable salt thereof, and one or more agents for controlling the release of tofacitinib therefrom.

[0227] In some embodiments, provided herein are delayed-release oral drug dosage forms comprising a delaying component coating a sustained-release drug component containing a JAK inhibitor. In some embodiments, the delaying component is a coating that elutes after a desired time period following administration to a human organism. In some embodiments, the sustained-release drug component is a core containing tofacitinib, or a pharmaceutically acceptable salt thereof, wherein the tofacitinib is homogeneously dispersed throughout the core.

[0228] In some embodiments, provided herein are delayed-release oral drug dosages comprising a delay component, a sustained-release drug component, and gastric retention features such as a void. In some embodiments, the delay component includes at least a portion thereof, such as a delay member, configured to release a JAK inhibitor from the delayed-release oral drug dosage form at a desired time after administration. In some embodiments, the delay component forms gastric retention features and accommodates the sustained-release drug component. In some embodiments, the portion of the delay component configured to release the JAK inhibitor, such as a delay member, is a plug, such as a corrosive plug.

[0229] In some embodiments, provided herein are delayed-release oral drug dosage forms comprising a delay component containing a sustained-release drug component comprising a JAK inhibitor. In some embodiments, the delayed-release oral drug dosage form is an osmotic dosage form. In some embodiments, the delay component or a portion thereof comprises a material that is permeable to body fluids. In some embodiments, the delay component or a portion thereof comprises a material that is selectively permeable. In some embodiments, the sustained-release drug component comprises a plurality of sustained-release beads comprising a JAK inhibitor. In some embodiments, the delay component comprises at least a portion thereof, such as a delay member, configured to release the JAK inhibitor from the delayed-release oral drug dosage form at a desired time after administration. In some embodiments, the sustained-release beads comprise a homogeneous mixture comprising tofacitinib or a pharmaceutically acceptable salt thereof, and one or more agents for controlling the release of tofacitinib therefrom. In some embodiments, the sustained-release beads are coated, such as being coated with an agent that controls the release of the JAK inhibitor.

[0230] keyboard.commercial batch In some embodiments, provided herein is a commercial batch of at least about 100 delayed-release oral drug dosage forms described herein. In some embodiments, the commercial batch includes at least about 250, 500, 750, 1,000, 2,500, 5,000, 7,500, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, or 100,000 of the delayed-release oral drug dosage forms described herein.

[0231] In some embodiments, the commercial batch has a standard deviation of about 0.1 or less, such as about 0.05 or less, for one or more of the following: the amount of JAK inhibitor in the delayed-release oral drug formulation, the weight of the delayed-release oral drug formulation, the maximum cross-sectional dimension of the delayed-release oral drug formulation, and the cross-sectional dimension perpendicular to the maximum cross-sectional dimension of the delayed-release oral drug formulation.

[0232] IV. Method for preparing delayed-release oral drug dosage forms In some embodiments, what is provided herein is a method for producing the delayed-release oral drug dosage forms described herein. In some embodiments, the method includes a three-dimensional (3D) printing technique for forming at least one of the components or parts thereof of the delayed-release oral drug dosage forms described herein. In some embodiments, the method includes an injection molding technique for forming at least one of the components or parts thereof of the delayed-release oral drug dosage forms described herein.

[0233] In some embodiments, a method for three-dimensional (3D) printing of a delayed-release oral drug dosage form described herein is provided, the method comprising printing the delayed-release oral drug dosage form by extruding material according to a layer-by-layer model of the delayed-release oral drug dosage form, each layer of the layer-by-layer model being printed by extruding, optionally, (a) a sustained-release drug component comprising a first corrosive material mixed with a JAK inhibitor, (b) a delay member comprising a second corrosive material not mixed with a JAK inhibitor, and (c) a shell. In some embodiments, the method further comprises generating a layer-by-layer model of the oral drug dosage form. In some embodiments, the extrusion is via melt extrusion deposition (MED). In some embodiments, the extrusion of each material is performed by different print heads.

[0234] In some embodiments, a method is provided for preparing a delayed-release tofacitinib oral drug dosage form by three-dimensional (3D) printing, wherein the delayed-release tofacitinib oral drug dosage form comprises a shell containing an insoluble material, a pharmaceutical core containing tofacitinib, and a delay member not containing tofacitinib, and the method comprises printing the delayed-release oral drug dosage form by extruding material according to a layer-by-layer model of the delayed-release oral drug dosage form, where each layer of the layer-by-layer model is printed by extruding, as necessary, a shell containing (a) a pharmaceutical core containing tofacitinib, (b) a delay member not containing tofacitinib, and (c) an insoluble material to a given layer.

[0235] As used herein, “printing,” “three-dimensional printing,” “3D printing,” “additive manufacturing,” or their equivalents refer to the process of producing three-dimensional objects, such as delayed-release oral drug dosage forms, layer by layer using digital design. The basic processes of three-dimensional printing are described in U.S. Patents 5,204,055, 5,260,009, 5,340,656, 5,387,380, 5,503,785, and 5,633,021. Additional U.S. patents and patent applications relating to three-dimensional printing include: U.S. Patents No. 5,490,962, No. 5,518,690, No. 5,869,170, No. 6,530,958, No. 6,280,771, No. 6,514,518, No. 6,471,992, No. 8,828,411, U.S. Publications 2002 / 0015728, 2002 / 0106412, 2003 / 0143268, 2003 / 0198677, and 2004 / 0005360. The contents of the above U.S. patents and patent applications are incorporated herein by reference in their entirety. In some embodiments, additive manufacturing techniques are used to produce the oral drug dosage forms described herein. In some embodiments, layer-by-layer techniques are used to produce the oral drug dosage forms described herein. Because 3D printing can handle a range of pharmaceutical materials and allows for localized control of both composition and architecture, it is highly suitable for the manufacture of oral drug dosage forms having complex geometric shapes and compositions according to the present invention.

[0236] In some embodiments, when used in relation to, for example, a sustained-release drug component layer or a delaying member layer, the layer refers to the composition of the components of an oral drug dosage form and may include multiple printed layers of the same material. In some embodiments, the layer has a predetermined packing density, such as a three-dimensionally printed packing density. In some embodiments, the layer, such as a sustained-release drug component layer or a delaying member layer, includes multiple printed layers ranging from about 5 to about 2500, such as about 10 to about 2500 printed layers, about 25 to about 100 printed layers, about 50 to about 200 printed layers, about 100 to about 200 printed layers, about 150 to about 250 printed layers, about 200 to about 250 printed layers, about 500 to about 1000 printed layers, or about 2000 to about 2400 printed layers. In some embodiments, the thickness of the printed layer is about 5 mm or less, for example, about 4 mm, 3 mm, 2 mm, 1 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm, 0.1 mm, 0.09 mm, 0.08 mm, 0.07 mm, 0.06 mm, 0.05 mm, 0.04 mm, 0.03 mm, 0.02 mm, or 0.01 mm or less. In some embodiments, the thickness of the printed layer is approximately 5 mm, 4 mm, 3 mm, 2 mm, 1 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm, 0.1 mm, 0.09 mm, 0.08 mm, 0.07 mm, 0.06 mm, 0.05 mm, 0.04 mm, 0.03 mm, 0.02 mm, or 0.01 mm.

[0237] From the perspectives of raw materials, equipment, and solidification, various 3D printing methods have been developed for manufacturing. These 3D printing methods include binder deposition (Gibson et al.,Additive Manufacturing Technologies:3D Printing,Rapid Prototyping and Direct Digital Manufacturing.,2 ed.Springer,New York,2015, Katstra et al.,Oral dosage forms fabricated by three dimensional printing,J Control Release,66,2000,Katstra et al.,Fabrication of complex oral delivery forms by three dimensional printing,Dissertation in Materials Science and Engineering,Massachusetts Institute of Technology,2001,Lipson et al.,Fabricated:The New World of 3D printing,John Wiley & Sons,Inc.,2013,Jonathan,Karim 3D printing in pharmaceutics:a new tool for designing customized drug delivery systems,Int J Pharm,499,2016),material injection (Jonathan,Karim,3D printing in pharmaceutics:a new tool for designing customized drug delivery See systems, Int J Pharm, 499, 2016, extrusion (see Gibson et al., Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping, and Direct Digital Manufacturing. 2nd ed. Springer, New York, 2015), and photopolymerization (see Melchels et al.)(See *A review on stereolithography and its application in biomedical engineering*, Biomaterials, 31, 2010.)

[0238] In some embodiments, the oral drug dosage forms described herein are 3D printed using an extrusion method. In some embodiments, the 3D printing method includes using a double-screw extrusion method. In the extrusion process, the material is extruded through a printing nozzle from a robot-operated print head. Unlike binder deposition, which requires a powder bed, the extrusion method can print on any substrate. A variety of materials, including thermoplastic materials, pastes and colloidal suspensions, silicones, and other semi-solids disclosed herein, can be extruded for three-dimensional printing. One extrusion printing method is molten extrusion deposition (MED), which uses the extruded material from the print head to print layers of material to form components of the oral drug dosage form. Another common type of extrusion printing is fusion deposition modeling, which uses a solid polymer filament for printing. In fusion deposition modeling, a gear system drives the filament into a heated nozzle assembly for extrusion (see Gibson et al., Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping, and Direct Digital Manufacturing, 2nd ed. Springer, New York, 2015).

[0239] In some embodiments, 3D printing is performed by melt extrusion deposition (MED). In some embodiments, the melt extrusion deposition technique includes preparing the material to be extruded, such as by preparing a powder in a hot melt extruder, and then feeding the material to a MED print head. The MED print head then extrudes the material to form a delayed-release oral drug dosage form in an additive manner (layer-by-layer deposition). In some embodiments, each material of the oral drug dosage form, such as the sustained-release drug component, delay member, and shell, is extruded from a different MED print head. In some embodiments, the MED print head extrudes the material according to instructions compliant with one or more gcode files. Exemplary MED techniques are disclosed, for example, in WO2018 / 210183, WO2019 / 137333, WO2018 / 137686 and U.S. Patent No. 10,201,503, each of which is incorporated herein by reference in whole.

[0240] In some embodiments, the melt extrusion deposition 3D printing technique includes (a) preparing each component material by melting and extruding the component material, wherein the component comprises a sustained-release drug component, a retarder, and a shell; and (b) printing a delayed-release oral drug dosage form. In some embodiments, the melt extrusion deposition 3D printing technique further includes preparing a printer head for printing. In some embodiments, preparing the sustained-release drug component includes melting and extruding the component material. In some embodiments, preparing the sustained-release drug component includes mixing the raw materials of the component material. In some embodiments, preparing the sustained-release drug component includes weighing each raw material of the component. In some embodiments, the materials of the sustained-release drug component include tofacitinib citrate, hydroxypropyl cellulose, vinylpyrrolidone-vinyl acetate copolymer (e.g., copovidone), and glycerin. In some embodiments, preparing the retarder includes weighing each raw material of the retarder, mixing the raw materials, and melting and extruding the formed retarder material. In some embodiments, the raw materials for the delaying member include hydroxypropyl cellulose, triethyl citrate, and titanium dioxide. In some embodiments, preparing the shell includes weighing each raw material of the shell, mixing the raw materials, and melting and extruding the formed shell material. In some embodiments, the raw materials for the shell include ammonia methacrylate copolymer type B, ethyl cellulose, stearic acid, and titanium dioxide. In some embodiments, preparing the printer head for printing includes filling the printer head with the formed component material. In some embodiments, preparing the printer head for printing includes setting the printer head temperature. In some embodiments, preparing the printer head for printing includes setting and applying feed pressure to the printer head. In some embodiments, applying feed pressure is completed after the printer head temperature has reached a predetermined level. In some embodiments, printing of the delayed-release oral drug dosage form is performed layer by layer (e.g., additive manufacturing).In some embodiments, the method includes using separate printer heads for each component material (e.g., a first printer head for ejecting a sustained-release drug component, a second printer head for ejecting a delay member, and a third printer head for ejecting a shell).

[0241] In some embodiments, the manufacturing method is designed and carried out based on a desired total number of delayed-release oral drug dosage forms to be manufactured during the manufacturing process. For example, in some embodiments, a smaller manufacturing process is desired (e.g., fewer than 1,000 delayed-release oral drug dosage forms for product development or clinical trials), and the manufacturing method includes preparing each component material (e.g., by weighing the raw materials of the component material, mixing the raw materials, and forming the component material by hot-melt extrusion), and then printing each delayed-release drug dosage form layer by layer (e.g., additive manufacturing). In some embodiments, a larger manufacturing process is desired (e.g., a commercial mass production process for more than 1,000 delayed-release oral drug dosage forms), and the manufacturing method includes preparing each component material (e.g., by weighing the raw materials of the component material, mixing the components, and forming the component material by hot-melt extrusion, where hot-melt extrusion is carried out using a twin-screw extruder), and then printing each delayed-release drug dosage form layer by layer (e.g., additive manufacturing). In some embodiments, the component material is formed at least partially using a twin-screw extruder. In some embodiments, a larger manufacturing process includes distributing the component material from the twin-screw extruder to each printer head via a flow distribution module. In some embodiments, a larger manufacturing process is carried out through the coordination of multiple modules. For example, in some embodiments, a manufacturing method includes the use of a material supply module for receiving a set of component material for printing, and a flow distribution module including a flow distribution plate, wherein the material supply module is configured to transport a single flow corresponding to the set of component material for printing to the flow distribution plate, and the flow distribution plate includes multiple channels for dividing the single flow into multiple flows, multiple nozzles, and one or more controllers for controlling the multiple nozzles to discharge multiple flows based on multiple nozzle-specific parameters. In some embodiments, the system further comprises a printing platform configured to receive the discharged multiple flows, and the printing platform is configured to move to form a batch of pharmaceutical products.In some embodiments, the system includes multiple printing platforms.

[0242] In some embodiments, 3D printing is performed by fused deposition modeling (FDM). In some embodiments, three-dimensional printing is performed by fused extrusion deposition or hot melt extrusion combined with a 3D printing technique such as FDM. In some embodiments, 3D printing is performed by non-filament FDM. In some embodiments, 3D printing is performed by inkjet printing. In some embodiments, 3D printing is performed by selective laser sintering (SLS). In some embodiments, 3D printing is performed by stereolithography (SLA or SL). In some embodiments, 3D printing is performed by PolyJet, Multi-Jet Printing System (MJP), Perfactory, Solid Object Ultraviolet-Laser Printer, Bioplotter, 3D Bioprinting, Rapid Freeze Prototyping, Benchtop System, Selective Deposition Lamination (SDL), Laminated Object Manufacturing (LOM), Ultrasonic Consolidation, ColorJet Printing (CJP), EOSINT Systems, Laser Engineered Net Shaping (LENS), and Aerosol Jet System, Electron Beam Melting (EBM), Laser CUSING (registered trademark), Selective Laser Melting (SLM), Phenix PX™ Series, Microsintering, Digital Part Materialization (DPM), or VX System.

[0243] In some embodiments, the 3D printing method described herein includes a continuous feeding method. In some embodiments, the 3D printing method described herein includes a batch feeding method.

[0244] In some embodiments, the method for producing the oral drug dosage forms described herein includes other methods, such as a combination of injection molding and 3D printing, and 3D printing techniques. In some embodiments, the shell is produced using injection molding, and one or more modulated emission portions are produced using 3D printing techniques.

[0245] The method instructions for 3D printing the drug dosage forms disclosed herein may be generated in a variety of ways, including direct coding, derivation from solid CAD models, or other means specific to the computer interface and application software of the 3D printer. These instructions may include information regarding the number and spatial arrangement of droplets, as well as information regarding general 3D printing parameters such as the drop spacing in each linear dimension (X, Y, Z) and the volume or mass of fluid per droplet. For a given set of materials, these parameters may be adjusted to refine the quality of the structure created. The overall resolution of the structure created is a function of powder particle size, fluid droplet size, printing parameters, and material properties.

[0246] In some embodiments, one or more components of a delayed-release oral drug dosage form are manufactured separately, such as by printing them separately, and then assembled to form the oral drug dosage form. In some embodiments, all components of a delayed-release oral drug dosage form are manufactured in a single manner, such as by printing them in a single manner, without requiring subsequent assembly.

[0247] The delayed-release oral drug dosage forms and their components described in this application can be printed on a commercial scale. For example, in some embodiments, 10,000 to 100,000 units of delayed-release oral drug dosage forms can be 3D printed per hour using the methods disclosed herein. In some embodiments, 10,000 to 100,000 units of oral drug dosage forms can be 3D printed per hour using the methods disclosed herein. In some embodiments, 10,000 to 100,000 units of dosage can be 3D printed per hour using the methods disclosed herein. In some embodiments, 10,000 to 100,000 units of dosage can be 3D printed per hour using the methods disclosed herein.

[0248] In some embodiments, the materials used to print oral drug dosage forms and dosage units, or their components, such as precursor drug dosage forms, are each ejected by different print heads. For example, in some embodiments, IR material and ER material, and optionally present, intermediate material and shell material, are each ejected by different print heads.

[0249] The 3D printing methods described herein include printing materials in any order that enables the production of oral drug dosage forms and dosage units, or their components, for example, precursor drug dosage forms disclosed herein.

[0250] In some embodiments, a method for 3D printing includes designing an oral drug dosage form or dosage unit, or its components, such as a precursor drug dosage form, entirely or partially, on a computer system. In some embodiments, the method includes inputting parameters of a desired drug release profile and / or oral drug dosage form and / or dosage unit and / or precursor drug dosage form into a computer system. In some embodiments, the method includes providing one or more parameters to be printed, such as layer surface area, thickness, drug mass fraction, and corrosion rate. In some embodiments, the method includes providing a desired drug release profile. In some embodiments, the method includes creating a virtual image of the item to be printed. In some embodiments, the method includes creating a computer model that includes predetermined parameters. In some embodiments, the method includes supplying predetermined parameters to a 3D printer and printing the item according to such predetermined parameters. In some embodiments, the method includes creating a 3D drawing of the item to be printed based on predetermined parameters, the 3D drawing being created on a computer system. In some embodiments, the method includes converting a 3D drawing, such as a slice, into a 3D printing code, such as G-code. In some embodiments, the method involves using a computer system to execute a 3D printing code, thereby printing according to the method described herein.

[0251] In some embodiments, provided herein are methods for three-dimensional (3D) printing of a delayed-release oral drug dosage form described herein, comprising: (a) ejecting a delay component or a portion thereof; and (b) ejecting a delayed-release drug component comprising a first corrosive material mixed with a JAK inhibitor. In some embodiments, the delay component, or a portion thereof such as a delay member or shell, is ejected before the ejection of the delayed-release drug component. In some embodiments, the delay component, or a portion thereof such as a delay member or shell, is ejected after the ejection of the delayed-release drug component. In some embodiments, ejecting the delay component comprises (i) ejecting a shell; and (ii) ejecting a delay member comprising a second corrosive material not mixed with a JAK inhibitor. In some embodiments, ejection is via melt extrusion deposition (MED). In some embodiments, ejection of the delay component, such as the ejection of the shell and the ejection of the delay member, is performed by different print heads.

[0252] In some embodiments, provided herein is a method for preparing a delayed-release tofacitinib oral drug dosage form by three-dimensional (3D) printing, wherein the delayed-release tofacitinib oral drug dosage form comprises a shell, a sustained-release drug component containing tofacitinib, and a delay member not containing tofacitinib, and the method comprises (a) dispensing the shell, (b) dispensing the sustained-release component containing tofacitinib, and (c) dispensing the delay member not containing tofacitinib. Using the method, the components of the delayed-release oral drug dosage form, or a portion thereof, can be dispensed in any order. In some embodiments, each component is dispensed sequentially in a specified order until completion. In some embodiments, the layers of the delayed-release oral drug dosage form are formed in layers, and each layer contains one or more components of the oral drug dosage form. In some embodiments, the method comprises dispensing the shell, the sustained-release component, and the delay member in that order. In some embodiments, the method includes extruding a delaying member, a sustained-release component, and a shell in that order. In some embodiments, the extrusion is via molten extrusion deposition (MED). In some embodiments, each material is extruded by a different print head.

[0253] In some embodiments, the foregoing provides a method for forming a delayed-release oral drug dosage form by injection molding. In some embodiments, the foregoing provides a method for injection molding an oral drug dosage form according to any one of claims 1 to 57, comprising: (a) injecting a hot melt of a shell material into a mold cavity to form a shell; (b) injecting a hot melt of a first corrosive material mixed with a JAK inhibitor into the shell to form a sustained-release drug component; and (c) injecting a hot melt of a second corrosive material not mixed with a JAK inhibitor into the shell to form a delay member.

[0254] In some embodiments, provided herein are methods for injection molding a delayed-release oral drug dosage form described herein, comprising: (a) hot-melting a shell material, a first corrosive material mixed with a JAK inhibitor, and a second corrosive material not mixed with a JAK inhibitor; (b) delivering each material to its respective injection unit; (c) injecting the hot-melt shell material into a mold cavity to form a shell; (d) allowing the shell to cool and opening the mold to release the shell; and (e) transferring the shell to a male mold and injecting the first corrosive material mixed with a JAK inhibitor. The method comprises (f) injecting to form a sustained-release drug component, (g) injecting a hot melt of a first corrosive material mixed with a JAK inhibitor to form a sustained-release drug component, (h) allowing the sustained-release drug component to cool and opening the mold to release the shell and the sustained-release drug component, (i) transferring the shell and the sustained-release drug component to a male mold and injecting a second corrosive material not mixed with a JAK inhibitor to form a delay member, (j) injecting a hole melt of the second corrosive material not mixed with a JAK inhibitor, and (g) discharging the delayed-release oral drug dosage form. In some embodiments, the injection unit is selected from the group consisting of a single-screw injection unit, a plunger injection unit, and a gear pump injection unit. In some embodiments, steps (c) to (j) are performed sequentially. In some embodiments, steps (c), (f), and (i) are performed simultaneously. In some embodiments, steps (e), (h), and (j) are performed simultaneously.

[0255] In some embodiments, the method provided includes preparing the materials for a dosage form (e.g., materials for each of the sustained-release drug components, delaying members, and shells), manufacturing the dosage form (e.g., via printing such as 3D printing), and one or more packaging steps. In some embodiments, preparing the materials for a dosage form includes weighing each of the raw materials for the material. In some embodiments, the packaging step includes packaging each individual dosage form in a separate container such as a laminate film and a pouch for pharmaceutical packaging. In some embodiments, the packaging step includes packaging several packaged dosage forms in a carton. In some embodiments, the method further includes one or more in-process quality control steps. For example, in some embodiments, after manufacturing the dosage form, the in-process quality control step includes one or more of evaluating the dosage form for appearance or its characteristics, evaluating the dosage form for weight, and evaluating the dosage form for dimensions. In some embodiments, in order to pass the in-process quality control step, the evaluated characteristics must be within a predetermined threshold. In some embodiments, after each dosage is packaged, an in-process quality control step includes evaluating the seal of each dosage form, for example, in terms of airtightness and / or filing volume. In some embodiments, after being packed into cartons, an in-process quality control step includes verifying the filing volume of the cartons.

[0256] V. Methods of treatment and / or prevention In some embodiments, provided herein are methods for treating and / or preventing a condition, comprising administering a delayed-release oral drug dosage form described herein. In some embodiments, the method comprises once daily administration of a delayed-release oral drug dosage form described herein.

[0257] In some embodiments, a method is provided for preventing morning stiffness, the method comprising administering a delayed-release oral drug dosage form described herein to a human individual, the delayed-release oral drug dosage form being administered the night before the morning in which prevention of morning stiffness is desired. In some embodiments, the delayed-release oral drug dosage form is administered at least about 6 hours before the morning in which the benefit is desired, such as at least about 7 hours, 8 hours, 9 hours, or 10 hours. In some embodiments, the delayed-release oral drug dosage form is administered within about 4 hours, such as about 3 hours, 2 hours, 1 hour, or 30 minutes before going to bed to fall asleep at night. In some embodiments, the method comprises once-daily administration of the delayed-release oral drug dosage form described herein.

[0258] In some embodiments, a method is provided for preventing morning stiffness caused by rheumatoid arthritis, the method comprising administering a delayed-release oral drug formulation described herein to a human individual, the delayed-release oral drug formulation being administered the night before the morning in which prevention of morning stiffness is desired. In some embodiments, the delayed-release oral drug formulation is administered at least about 6 hours before the morning in which the benefit is desired, such as at least about 7 hours, 8 hours, 9 hours, or 10 hours. In some embodiments, the delayed-release oral drug formulation is administered within about 4 hours, such as about 3 hours, 2 hours, 1 hour, or 30 minutes before going to bed to fall asleep at night. In some embodiments, the method comprises once-daily administration of the delayed-release oral drug formulation described herein.

[0259] In some embodiments, a method is provided for preventing morning stiffness caused by psoriatic arthritis, the method comprising administering a delayed-release oral drug formulation described herein to a human individual, the delayed-release oral drug formulation being administered the night before the morning in which prevention of morning stiffness is desired. In some embodiments, the delayed-release oral drug formulation is administered at least about 6 hours before the morning in which the benefit is desired, such as at least about 7 hours, 8 hours, 9 hours, or 10 hours. In some embodiments, the delayed-release oral drug formulation is administered within about 4 hours, such as about 3 hours, 2 hours, 1 hour, or 30 minutes before going to bed to fall asleep at night. In some embodiments, the method comprises once-daily administration of the delayed-release oral drug formulation described herein.

[0260] In some embodiments, a method is provided for treating ulcerative colitis, comprising administering a delayed-release oral drug dosage form described herein to a human individual. In some embodiments, a method is provided for preventing and / or alleviating symptoms associated with ulcerative colitis, such as morning symptoms, comprising administering a delayed-release oral drug dosage form described herein to a human individual. In some embodiments, the delayed-release oral drug dosage form is administered the night before the morning in which the benefit is desired. In some embodiments, the delayed-release oral drug dosage form is administered at least about 6 hours before the morning in which the benefit is desired, such as at least about 7 hours, 8 hours, 9 hours, or 10 hours. In some embodiments, the delayed-release oral drug dosage form is administered within about 4 hours, such as about 3 hours, 2 hours, 1 hour, or 30 minutes before going to sleep for the night. In some embodiments, the method comprises once-daily administration of the delayed-release oral drug dosage form described herein.

[0261] In some embodiments, the dosage forms provided herein are administered when the subject is in a fed state. In some embodiments, the dosage forms provided herein are administered when the subject is in a fasted state. In some embodiments, the dosage forms provided herein do not show significant differences in drug dissolution and / or absorption in a fed state compared to a fasted state.

[0262] Those skilled in the art will recognize that several embodiments are possible within the scope and spirit of the disclosure of this application. The disclosure is further illustrated by the following embodiments, which should not be construed as limiting the disclosure in scope or spirit to the specific procedures described herein. [Examples]

[0263] Example 1 This embodiment demonstrates the design and testing of two delayed-release oral drug formulations containing a fixed amount of a JAK inhibitor, namely tofacitinib, having a desired drug release profile.

[0264] Two oral drug dosage forms were prepared and referred to below as Caplet A and Caplet B. The 3D structures of the caplet oral drug dosage forms were designed using Solidworks 2014. Schematic diagrams of Caplet A and B are shown in Figures 2A and 2B. The dimensions and component composition of the prepared dosage forms were as specified in the specifications. Caplets A and B were 3D printed using the MED 3D printing system. Both Caplets A and B contained 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib). The retarder was composed of a corrosive polymer matrix. The shell was composed of a water-insoluble polymer.

[0265] The in vitro dissolution rates of caplets A and B were tested and compared to the commercially available tofacitinib-containing drug, XELJANZXR (Pfizer). XELJANZXR also contains 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib). Dissolution rates were measured using the same method as for tofacitinib citrate ER tablets in the current FDA dissolution method database. Briefly, caplets A and B were eluted in 900 mL of pH 6.8 phosphate buffer in a 50 rpm drug dissolution device USPII (paddle), with the delay element facing downwards in the phosphate buffer. The cumulative percentage of dissolution was measured at 1-hour intervals until the dissolution of the corrosive material was complete. The dissolution profile for XELJANZXR was obtained using the same method. Dissolution experiments for each dosage form were repeated six times.

[0266] The elution profiles of caplets A and B compared to XELJANZXR are shown in Figures 3 and 4, respectively. Due to their delayed release characteristics, both caplets A and B exhibited longer elution profiles compared to XELJANZXR. XELJANZXR eluted 50% in 2-3 hours and reached 90% elution in 7 hours. Caplet A eluted 50% between 6-7 hours and reached 90% elution between 9-10 hours. Caplet B showed a longer elution delay, eluting 50% in 8-9 hours and 90% eluting in 12-13 hours. The results are consistent with the thicker delay element (0.7 mm) of caplet B compared to the delay element thickness (0.4 mm) of caplet A.

[0267] Caplet A, Caplet B, and XELJANZXR (RLD tablets) were used in in vivo pharmacokinetic studies in non-GLP-administered male beagle dogs. After a single oral administration of each drug dosage form, blood samples were collected from the jugular vein at predetermined intervals (1-hour intervals up to 24 hours after administration). Plasma concentrations of the drugs were determined by LC-MS / MS analysis (n=5 male beagle dogs). The mean plasma concentration curves for the tested formulations are shown in Figures 5 and 6.

[0268] Both Caplet A and Caplet B were used in vivo in plasma C maxThe effective delay was observed. As shown in Figure 5, caplet A achieved the desired rapid initial increase in plasma drug concentration after delay. max Compared to XELJANZXR, the release was delayed by approximately 2 hours, and the change in AUC between the two dosage forms was minimal. As shown in Figure 6, Caplet B had a delayed release of tofacitinib for approximately 3 hours, followed by an extended phase of drug delivery. Caplet B was delayed by more than 3 hours compared to XELJANZXR, with C12 being released between 8 and 9 hours post-administration. max It reached its goal.

[0269] Example 2 This embodiment demonstrates the design and testing of a portion of a delayed-release oral drug dosage form containing a fixed amount of a JAK inhibitor, namely tofacitinib. The portion of the oral drug dosage form was designed without a delay member containing a shell and a delayed-release drug component comprising a first corrosive material mixed with the JAK inhibitor used in caplets A and B of Example 1, and without a second corrosive material not mixed with the JAK inhibitor. Such portions of the oral drug dosage form are useful for studying the release of the JAK inhibitor from the oral drug dosage form without the delay provided by a delay member.

[0270] An oral drug dosage form was fabricated and hereafter referred to as Caplet C. The 3D structure of the Caplet oral drug dosage form was designed using Solidworks 2014. The dimensions and component composition of the prepared dosage form were as described in the specifications. Caplet C was 3D printed using the MED 3D printing system. Dosage form C contained 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib). The shell was composed of a water-insoluble polymer.

[0271] The in vitro dissolution rate of Caplet C was tested and compared with commercially available tofacitinib-containing drugs, XELJANZXR (Pfizer), and Caplets A and B from Example 1. XELJANZXR and Caplets A and B all contained 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib). The dissolution rate was measured using the same method as for tofacitinib citrate ER tablets in the current FDA dissolution method database. Briefly, Caplets A, B, and C were eluted in 900 mL of pH 6.8 phosphate buffer in a 50 rpm USPII (paddle) drug dissolution device, with the delay element facing downwards in the phosphate buffer. The cumulative percentage of dissolution was measured at 1-hour intervals until the dissolution of corrosive materials was complete. The dissolution profile for XELJANZXR was obtained using the same method. Dissolution experiments for each dosage form were repeated six times.

[0272] Figure 7 shows the dissolution profiles of caplets A, B, and C compared to XELJANZXR. Caplet C reached 50% dissolution in 3–4 hours and 90% dissolution in 7 hours, which was similar to XELJANZXR, which reached 50% dissolution in 2–3 hours and 90% dissolution in 7 hours. Adjustments to the sustained-release drug component containing a first corrosive material containing a JAK inhibitor can be made so that the dissolution profile of caplet C is more similar to that of XeljanzXR. Due to the presence of a delaying member containing a second corrosive material not mixed with the JAK inhibitor, caplets A and B have extended dissolution profiles compared to those of XELJANZXR and caplet C.

[0273] Example 3 This embodiment demonstrates a study of the pharmacokinetic (PK) profiles of caplets A and B (from Example 1) compared to XeljanzXR in human subjects.

[0274] Sixteen healthy subjects participated in the PK study. The subjects were divided into four groups and participated in a public, single-dose crossover experiment (four cycles per group). The experimental design is shown in Table 1. X represents a simulated "real-world" scenario in which subjects ate dinner at 18:00 and a light meal at 21:30 before administration of caplet A. Caplet A was then administered immediately before bedtime (22:00). Y represents a simulated "real-world" scenario in which subjects ate dinner at 18:00 and a light meal at 21:30 before administration of caplet B. Caplet B was then administered immediately before bedtime (22:00). Z represents a simulated "real-world" scenario in which subjects ate dinner at 18:00 and then administered caplet B immediately before bedtime (22:00). W represented the control group, in which subjects took XELJANZ XR at 8:00 AM after fasting for at least 10 hours. Each group was subjected to different experimental conditions (X, Y, Z, or W) during each cycle of the experiment. [Table 1]

[0275] The PK parameters are shown in Table 2, and the resulting PK curves are shown in Figure 8. Figure 9 shows the Xeljanz XR, a dashed overlay of the target PK curve (Xeljanz XR delayed by 14 hours), and the PK curve for Couplet A with a snack at 21:30. [Table 2]

[0276] Average C in Table 2 max and T max This is the C of each of the 16 subjects. max and T max The calculation was performed from the plasma concentration-time curve, which shows the average at each time point, and therefore the fitted C curve. max and T max The value is average C max and T maxThis may differ. Based on the above results, the retarding member in caplets A and B, which contains corrosive material not mixed with the JAK inhibitor, effectively T lag and T max This was delayed. As the thickness of the delay member increased (comparison of couplet A and couplet B), T lag and T max The AUC of couplet A increased accordingly. 0-inf and C max The absorption rates for Xeljanz XR were 86.1% (90% confidence interval: 74.9%–98.9%) and 60.7% (90% confidence interval: 49.5%–74.4%), respectively. The AUCs for dosage forms A and B were similar to those for Xeljanz XR. A light meal at 21:30 did not significantly affect the absorption of tofacitinib.

[0277] Example 4 This embodiment demonstrates the design and testing of a delayed-release oral drug dosage form containing a fixed amount of a JAK inhibitor, namely tofacitinib, having a desired drug release profile.

[0278] An oral drug dosage form was fabricated and referred to below as Caplet 2A. The 3D structure of the caplet oral drug dosage form was designed using Solidworks 2014. A schematic diagram of Caplet 2A is shown in Figures 2A and 2B. The dimensions and component composition of the prepared dosage form were as described in the specifications. Caplet 2A containing 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib) was 3D printed using the MED3D printing system. The retarder was composed of a corrosive polymer matrix that did not contain a JAK inhibitor. The shell was composed of a water-insoluble polymer.

[0279] The in vitro elution profile of caplet 2A was measured as described in Example 1. The elution profile of caplet 2A is shown in Figure 10. Caplet 2A reached 50% elution in 7-8 hours, which was longer than the time it took for caplet A to reach 50% elution (6-7 hours). Caplet 2A reached 90% elution in 9-10 hours.

[0280] The PK profile of Caplet 2A was obtained in human subjects according to the following experimental design: A single-center, randomized, open-access, single-dose, two-cycle crossover early pharmacokinetic (PK) clinical trial was conducted according to the experimental design shown in Table 3 below. Subjects were given dinner at 18:00, followed by a single oral dose of Caplet 2A at 22:00, or a single oral dose of Xeljanz XR in the morning after at least 10 hours of overnight fasting. [Table 3]

[0281] Example 5 This embodiment demonstrates the design and testing of a delayed-release oral drug dosage form containing a fixed amount of a JAK inhibitor, namely tofacitinib, having a desired drug release profile.

[0282] Delayed-release oral drug dosage forms D to O, shown in Figures 11A to 11F, were fabricated. The dimensions and component composition of the prepared dosage forms were as specified in the specifications. The 3D structures of the oral drug dosage forms were designed using Solidworks 2014. The oral drug dosage forms were 3D printed using the MED3D printing system. Each oral drug dosage form contained approximately 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib). The delaying element consisted of a corrosive polymer matrix. The shell consisted of a water-insoluble polymer.

[0283] The in vitro dissolution rate of dosage form D was tested and compared with that of the commercially available tofacitinib-containing drug, XELJANZXR (Pfizer). XELJANZXR contains 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib). The dissolution rate was measured using the same method as described in Example 1.

[0284] Figure 12 shows the dissolution profile of dosage form D compared to XELJANZXR. Due to its delayed-release characteristics, dosage form D had a longer dissolution profile compared to XELJANZXR. XELJANZXR reached 50% dissolution in 2-3 hours and 90% dissolution in 7 hours. Dosage form D reached 50% dissolution between 6-7 hours and 90% dissolution in approximately 10 hours.

[0285] Dosage forms D and XELJANZXR (RLD tablets) were subjected to in vivo pharmacokinetic studies in non-GLP-administered male beagle dogs, as described in Example 1. The mean plasma concentration curves of the tested formulations are shown in Figure 13.

[0286] Dosage form D is used in vivo in plasma C max It demonstrated an effective delay. As shown in Figure 13, caplet E achieved the desired rapid initial increase in plasma drug concentration after delay. max Compared to XELJANZXR, the reaction was delayed by approximately 2 hours, and the change in AUC between the two dosage forms was minimal.

[0287] The in vitro dissolution rates of dosage forms E and F were tested. The dissolution rates were measured using the same method as described in Example 1.

[0288] The dissolution profiles for dosage forms E and F are shown in Figure 14. Dosage form E reached 50% dissolution in approximately 6 hours and 90% dissolution between 9 and 10 hours. Dosage form F reached 50% dissolution between 7 and 8 hours and 90% dissolution in approximately 13 hours.

[0289] Dosage forms E and F, as well as XELJANZXR (RLD tablets), were subjected to in vivo pharmacokinetic studies in non-GLP-administered male beagle dogs, as described in Example 1. The mean plasma concentration curves of the tested formulations are shown in Figure 15.

[0290] Dosage forms E and F are used in vivo in plasma C max This demonstrated an effective delay. As shown in Figure 15, both dosage forms E and F achieved the desired, rapid initial increase in plasma drug concentration after delay. maxCompared to XELJANZXR, the T of dosage form F was delayed by approximately 1 hour. max Compared to XELJANZXR, the reaction was delayed by approximately 2 hours, and the change in AUC between the two dosage forms was minimal.

[0291] The in vitro dissolution rates of dosage forms G and H were tested and compared with the commercially available tofacitinib-containing drug, XELJANZXR (Pfizer). XELJANZXR contains 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib). The dissolution rate was measured using the same method as described in Example 1.

[0292] Figure 16 shows the elution profiles of dosage forms G and H compared to XELJANZXR. Due to their delayed-release characteristics, dosage forms G and H had longer elution profiles compared to XELJANZXR. XELJANZXR eluted 50% in 2-3 hours and reached 90% elution in 7 hours. Dosage form G eluted 50% in approximately 6 hours and reached 90% between 6 and 7 hours. Dosage form H eluted 50% between 7 and 8 hours and reached 90% between 8 and 9 hours. The results are consistent with the thicker delay element (1.2 mm) of dosage form H compared to the delay element thickness (0.8 mm) of dosage form G.

[0293] Dosage forms G and H, as well as XELJANZXR (RLD tablets), were subjected to in vivo pharmacokinetic studies in non-GLP-administered male beagle dogs, as described in Example 1. The mean plasma concentration curves of the tested formulations are shown in Figure 17.

[0294] Dosage forms G and H are used in vivo in plasma C max This demonstrated an effective delay. As shown in Figure 17, both dosage forms G and H achieved the desired rapid initial increase in plasma drug concentration after delay. max Compared to XELJANZXR, the T of dosage form H was delayed by approximately 2 hours. max Compared to XELJANZXR, the reaction was delayed by approximately 4 hours, and the change in AUC between the two dosage forms was minimal.

[0295] The in vitro dissolution rates of dosage forms I, J, and K were tested and compared to the commercially available tofacitinib-containing drug, XELJANZXR (Pfizer). XELJANZXR also contains 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib). The dissolution rates were measured using the same method as described in Example 1.

[0296] Figure 18 shows the dissolution profiles of dosage forms I, J, and K compared to XELJANZXR. Due to their delayed-release characteristics, dosage forms I, J, and K had longer dissolution profiles compared to XELJANZXR. XELJANZXR reached 50% dissolution in 2-3 hours and 90% dissolution in 7 hours. Dosage form I reached 50% dissolution in approximately 8 hours and 90% between 9-10 hours. Dosage form J reached 50% dissolution in approximately 5 hours and 90% between approximately 8 hours. Dosage form K reached 50% dissolution in approximately 7 hours and 90% between 9-10 hours.

[0297] Dosage forms I, J, K, and XELJANZXR (RLD tablets) were subjected to in vivo pharmacokinetic studies in non-GLP-administered male beagle dogs, as described in Example 1. The mean plasma concentration curves of the tested formulations are shown in Figure 19.

[0298] Dosage forms I, J, and K are used in vivo in plasma C max This demonstrated an effective delay. As shown in Figure 19, dosage forms I, J, and K achieved the desired rapid initial increase in plasma drug concentration after delay. max Compared to XELJANZXR, the T of dosage form I was delayed by approximately 2 hours. max Compared to XELJANZXR, the reaction was delayed by approximately 4 hours, and the change in AUC between the two dosage forms was minimal.

[0299] The in vitro dissolution rates of dosage forms L, M, and N were tested and compared to the commercially available tofacitinib-containing drug, XELJANZXR (Pfizer). XELJANZXR contains 17.77 mg of tofacitinib citrate (equivalent to 11 mg of tofacitinib). The dissolution rate was measured using the same method as described in Example 1.

[0300] Figure 20 shows the dissolution profiles of dosage forms L, M, and N compared to XELJANZXR. Due to their delayed-release characteristics, dosage forms L, M, and N had longer dissolution profiles compared to XELJANZXR. XELJANZXR reached 50% dissolution in 2-3 hours and 90% dissolution in 7 hours. Dosage form L reached 50% dissolution between 7-8 hours and 90% between 8-9 hours. Dosage form M reached 50% dissolution between 7-8 hours and 90% between 9-10 hours. Dosage form N reached 50% dissolution in approximately 8 hours and 90% between 10-11 hours.

[0301] Dosage forms L, M, and N, as well as XELJANZ XR (RLD tablets), were subjected to in vivo pharmacokinetic studies in non-GLP-administered male beagle dogs, as described in Example 1. The pharmacokinetic curves for dosage forms L and M, and Xeljanz XR are shown in Figure 21. The pharmacokinetic curves for dosage form O and Xeljanz XR are shown in Figure 22.

[0302] Dosage forms L, M, and N are used in vivo in plasma C max The effective delay was observed. As shown in Figures 21 and 22, dosage forms L, M, and N achieved the desired, rapid initial increase in plasma drug concentration after delay. max Compared to XELJANZXR, the effect was delayed by approximately 4 hours, and the change in AUC between dosage forms L, M, and N was minimal.

[0303] The in vitro dissolution rate of dosage form O was tested. The dissolution rate was measured using the same method as described in Example 1.

[0304] Figure 23 shows the dissolution profile of dosage form O compared to XELJANZXR. Dosage form O reached 50% dissolution between 5 and 6 hours and 90% dissolution between 8 and 9 hours.

Claims

1. 1. A delayed sustained release oral drug dosage form of a Janus kinase (JAK) inhibitor, comprising: a sustained release drug composition comprising a first erodible material mixed with the JAK inhibitor; a delay component; A delayed sustained release oral drug dosage form, wherein the delay component prevents release of the JAK inhibitor from the delayed sustained release oral drug dosage form for about 2 hours to about 6 hours after administration of the delayed sustained release oral drug dosage form to a human individual.

2. The delay component is a delay element comprising a second corrosive material that is not mixed with the JAK inhibitor; a shell; 2. The delayed sustained release oral drug dosage form of claim 1, wherein the delay component completely surrounds the sustained release drug component.

3. The delayed sustained release oral drug dosage form of claim 2, wherein the JAK inhibitor is tofacitinib or a pharma- ceutically acceptable salt thereof, the sustained release drug component is a layer having a top surface and a bottom surface, the thickness measured between the top surface and the bottom surface is substantially consistent, the sustained release drug component is embedded in the shell such that the bottom and side surfaces of the sustained release drug component are in direct contact with the shell, and the top surface of the sustained release drug component is not in direct contact with the shell.

4. The delayed sustained release oral drug dosage form of claim 3, wherein the sustained release drug component has a thickness of about 0.2 mm to about 5 mm.

5. The delayed sustained release oral drug dosage form of claim 3, wherein the first erodible material of the sustained release drug component comprises one or more of hydroxypropylcellulose (HPC EF), vinylpyrrolidone-vinyl acetate copolymer (VA64), triethyl citrate (TEC), and glycerin.

6. 3. The delayed sustained release oral drug dosage form of claim 2, wherein the retardation member is a layer having a top surface and a bottom surface, the thickness measured between the top surface and the bottom surface is substantially consistent, and the bottom surface of the retardation member, or a portion thereof, is in direct contact with the top layer of the sustained release drug component.

7. The delayed sustained release oral drug dosage form of claim 6, wherein the bottom surface of the retarding member is larger than the top surface of the sustained release drug component.

8. The delayed sustained release oral drug dosage form of claim 6, wherein the retardation member has a thickness of about 0.2 mm to about 5 mm.

9. 7. The delayed sustained release oral drug dosage form of claim 6, wherein the delay member and the shell are configured to prevent the JAK inhibitor from being released from the delayed sustained release oral drug dosage form until the delay member erodes, and wherein the delay completely dissolves in about 6 hours after administration of the delayed sustained release oral drug dosage form to the human individual.

10. The delayed sustained release oral drug dosage form of claim 6, wherein the delay component prevents the release of the JAK inhibitor from the delayed sustained release oral drug dosage form for about 2 hours to about 4 hours after administration of the delayed sustained release oral drug dosage form to a human individual.

11. The delayed sustained release oral drug dosage form of claim 6, wherein the second corrodible material of the delay layer comprises one or more of hydroxypropyl cellulose (HPC EF), triethyl citrate (TEC), and titanium dioxide.

12. 3. The delayed sustained release oral drug dosage form of claim 2, wherein the shell comprises an isolating material that is impermeable to body fluids.

13. The delayed sustained release oral drug dosage form of claim 12, wherein the isolating material is a non-erodible material or an erodible material having a pH-sensitive erosion and / or erosion rate that allows complete release of the JAK inhibitor from the delayed sustained release oral drug dosage form prior to exposure of the sustained release drug component to body fluids due to erosion of the shell.

14. The delayed sustained release oral drug dosage form of claim 12, wherein the shell has a minimum thickness of at least about 0.4 mm.

15. The delayed sustained release oral pharmaceutical dosage form of claim 14, wherein the shell comprises one or more of ammonio methacrylate copolymer type B, ethyl cellulose, stearic acid, and titanium dioxide.

16. The sustained release drug component is (i) 30% or less of the total JAK inhibitor is released one hour after complete erosion of the delay component or portion thereof; (ii) 35% or more and 75% or less of the total JAK inhibitor is released 2.5 hours after complete erosion of the retardation component or portion thereof; and (iii) 75% or more of the total JAK inhibitor is released 5 hours after complete erosion of the delay component or a portion thereof.

17. T max The delayed sustained release oral pharmaceutical dosage form according to any one of claims 1 to 15, wherein the delayed release occurs within about 6 hours after complete erosion of the delay component or a portion thereof.

18. 1. A method for preparing a delayed sustained release tofacitinib oral drug dosage form by three-dimensional (3D) printing, comprising: The delayed sustained release tofacitinib oral drug dosage form comprises a shell containing an insoluble material, a pharmaceutical core containing tofacitinib, and a delay member not containing tofacitinib; The method includes dispensing material according to a layer-by-layer model of the delayed sustained release oral drug dosage form to print the delayed sustained release oral drug dosage form, wherein each layer of the layer-by-layer model optionally comprises, for a layer: (a) a pharmaceutical core containing tofacitinib; (b) the delay element does not contain tofacitinib, and (c) printing by ejecting said shell comprising an insoluble material.

19. A method for injection molding an oral pharmaceutical dosage form according to any one of claims 1 to 15, comprising the steps of: (a) injecting a hot melt of the shell material into a mold cavity to form the shell; (b) injecting a hot melt of the first erodible material mixed with a JAK inhibitor into the shell to form the sustained release drug component; (c) injecting a hot melt of the second corrodible material, unmixed with the JAK inhibitor, into the shell to form the delay member.

20. 16. A delayed sustained release oral drug dosage form according to any one of claims 1 to 15 for preventing morning stiffness caused by rheumatoid arthritis or psoriatic arthritis, characterized in that said delayed sustained release oral drug dosage form is administered within about 1 hour of going to bed.